Study Protocol 
 
 
Title:  A Phase 1, Randomized, Double -Blind, Single Ascending Dose Study to  
Determine the Safety, Tolerability, and Pharmacokinetics of CD388 
Subcutaneous Administration in Healthy Japanese Subjects 
Study ID: [REMOVED]  
Document Date:  12 DEC  2022 
 
Cidara Therapeutics, Inc. Protocol CD388.SQ.1.03 
CD388 Injection 
Amendment 1 Confidential Page 1 of 74 PROTOCOL TITLE PAGE 
Title A Phase 1, Randomized, Double-Blind, Single Ascending Dose Study to 
Determine the Safety, Tolerability , and Pharmacokinetics of CD388 
Subcutaneous Administration in Healthy Japanese Subjects 
Study Drug CD388 Injection 
Original Protocol 09AUG2022 
Amendment 1 12DEC2022 
Sponsor Cidara Therapeutics, Inc. 
6310 Nancy Ridge Dr., Suite 101 
San Diego, California 92121, USA 
Telephone: +1.858.752.6170 
Facsimile: +1.858.408.3509 
Sponsor Medical Monitor Ozlem Equils, MD, FAAP 
Cidara Therapeutics, Inc. 
6310 Nancy Ridge Dr., Suite 101 
San Diego, California 92121, USA 
Mobile: +1.310.595.4094 
Email: oequils@cidara.com  
Sponsor Clinical Project Manager Joaquin Sosa 
Cidara Therapeutics, Inc. 
6310 Nancy Ridge Drive, Suite 101 San Diego, California 92121, USA 
Office: +1.858.249.7394
Email: jsosa@cidara.com
Regulatory Agency Identifier 
Number(s): IND 155,536 
Confidentiality Statement: 
This document is a confidential communication from Cidara Therapeutics, Inc. Acceptance of this 
document constitutes an agreement by the recipient(s) that no information contained herein will be published or disclosed without prior written approval from Cida ra Therapeutics, Inc., except 
that this document may be disclosed to appropriate Institutional Review Boards and/or Ethics Committees under the condition that they are also required to maintain confidentiality. 
Cidara Therapeutics, Inc. Protocol CD388.SQ.1.03
CD388 Injection
Amendment 1 Confidential Page 2 of 74PROTOCOL APPROV AL PAGE
Protocol: CD388.SQ.1.03
A Phase 1, Randomized, Double-Blind, Single Ascending Dose Study to Determine the 
Safety, Tolerability, and Pharmacokinetics  of CD388 Subcutaneous Administration 
in Healthy Japanese Subjects
Original Protocol: 09AUG2022
Amendment 1: 12DEC2022
SPONSOR SIGNATURE
Signature
Taylor Sandison, MD, MPH
Chief Medical Officer
Cidara Therapeutics, Inc.Date

Cidara Therapeutics, Inc.  Protocol CD388.SQ.1.03 
CD388 Injection 
Amendment 1 Confidential  Page 3 of 74 1. PROTOCOL SYNOPSIS 
Sponsor: Cidara Therapeutics Inc., San Diego, CA 
Product Name: CD388 Injection  
Active Ingredients: CD388 
Protocol Title: A Phase 1, Randomized, Double-Blind, Single Ascending Dose Study to Determine the Safety, 
Tolerability, and Pharmacokinetics of  CD388 Subcutaneous Ad ministration in Healt hy Japanese Subjects  
Planned Study Centers: Single center in the United States  
Phase of Development: 1 
Indication:  Influenza virus infection  
IND Number: 155,536  
Objectives and Endpoints 
Objectives Endpoints 
Primary  
x To determine the safety and tolerability 
profile of CD388 Injection when dosed by 
subcutaneous (SQ) administration as a single 
dose to healthy Japanese adult subjects. x Incidence and severity of treatment-emergent adverse events (TEAEs), including but not limited to adverse events (AEs) and serious adverse events (SAEs) (including systemic reactogenicity/
injection site reactions and hypersensitivity 
reactions), AEs leading to study drug discontinuation and/or study withdrawal, vital 
signs, 12-lead electrocardiograms (ECGs), 
and clinical laboratory tests (including hematology, coagulation, serum chemistry, and urinalysis), after a single dose of CD388. 
Secondary  
x To determine the plasma pharmacokinetic (PK) profile of CD388 Injection when dosed 
by SQ administration as a single dose to 
healthy Japanese adult subjects. x Pharmacokinetic parameters following CD388 Injection administration: maximum plasma concentration (C
max), time to maximum plasma 
concentration (T max), terminal elimination half-life 
(tÂ½), apparent clearance (CL/F), apparent volume 
of distribution (V Z/F), area under the plasma 
concentration-time curve from time 0 to time of last quantifiable sample (AUC
0-last), area under the 
plasma concentration-time curve from time 0 
extrapolated to infinity (AUC 0-Â’). 
Exploratory 
x To evaluate the PK profile of CD388 in upper 
respiratory tract after SQ administration as 
a single dose to healthy Japanese adult 
subjects. x Pharmacokinetic parameters following CD388 Injection administration: maximum nasopharyngeal (NP) concentration (C
max), time to 
maximum NP concentration (T max), area under the 
NP concentration-time curve from time 0 to time of last quantifiable sample (AUC
0-last). 
  
Cidara Therapeutics, Inc.  Protocol CD388.SQ.1.03 
CD388 Injection 
Amendment 1 Confidential  Page 4 of 74   
Objectives  Endpoints  
Exploratory (continued)   
x To evaluate biomarkers that may be 
associated with safety, reactogenicity, 
and immunogenicity after CD388 Injection. x Results of the analyses of exploratory biomarkers (including but not limited to cytokines, 
chemokines, acute phase reactants, etc.). 
x To evaluate CD388 immunogenicity. x Anti-drug antibody (ADA) titers in blood (plasma 
or serum). 
x To explore the effect of CD388 Injection on 
the occurrence of influenza-like illness 
(during flu season). x Occurrence of influenza-like illness reporting 
during the outpatient follow-up period. 
  
Study Design  
This is a Phase 1, single-center, prospective, randomized, double-blind study of ascending single doses of CD388 
Injection administered SQ to healthy Japanese adult subjects. The goals are to assess safety, tolerability, and PK 
of CD388.  
Subjects will be randomized to recei ve a single dose of CD388 or placeb o administered via SQ injection 
(treatment assignment is blinded) according to the design in the table below.  
Number of Subjects (N = 27) 
Cohort: dose CD388 
(n = 21) Placebo 
(n = 6) 
Cohort 1: 50 mg 7 2 
Cohort 2: 150 mg 7 2 
Cohort 3: 450 mg 7 2 
Note: A subject may not receive treatment in more than one cohort.  
After 50% of Cohort 1 subjects have completed study drug  administration and have undergone protocol-specified 
procedures and DVVHVVPHQWVIRUÂ• 10 days, the Principal Investigator (PI) and Sponsor will review blinded safety 
data: AEs (including systemic reactoge nicity/injection site reactions, hype rsensitivity reactions, and adverse 
events of special interest [AESIs]), vital signs, 12-lead ECGs, and clinical laboratory results (hematology, 
coagulation, serum chemistry, urinalys is) to determine the safety and tolera bility of the study drug. The incidence 
and severity of AEs, and any adverse changes in vital signs, clinical laboratory findings, and ECGs will be 
considered when determining safety and tolerability of study drug. If the dose is determined to be safe and well WROHUDWHGÂ• 10 days after dosing, Cohort 2 will be enrolled. Enrollment of the remain ing 50% of Cohort 1 will 
continue while the safety data of the first 50% of Cohort 1 is being reviewed. Similar processes will be followed for dose escalation from Cohort 2 to Cohort 3. 
The Schedule of Events is presented in  Table 1 . All subjects will be admitted to the clinical research unit (CRU) 
for observation and safety assessments from Day -1 (check-in) to Day 14. Subjects will be monitored for AEs 
(including systemic reactogenicity/injection site reac tions, hypersensitivity reactions and AESIs) and SAEs 
throughout the study until the final study visit after dosing.  Safety will also be asse ssed by physical examinations, 
ECGs, vital signs measurements, and laboratory evaluations (hematology, coagulation, serum chemistry, 
urinalysis) at various time points during and after the CRU stay. Concomitant medication use will be recorded throughout the study.  
Blood samples for PK and ADA assessments will be collect ed throughout the study. To maintain the blind, 
samples will be collected from all subjects; however, only samples from  the CD388 Injection group will be 
analyzed (using validated assays) by an unblinded central bioanalytical laboratory. Additional blood samples will 
be collected for pharmacogenomics and exploratory biomarker evaluation. 
Cidara Therapeutics, Inc.  Protocol CD388.SQ.1.03 
CD388 Injection 
Amendment 1 Confidential  Page 5 of 74 Respiratory tract infection (RTI) su rveillance will be conducted during th e outpatient phase of the study from 
CRU discharge through the Day 120/165 outpatient visit or a lab-confirmed influenza infection, whichever occurs 
first. Subjects will be provided nasal/throat swab kits (for detection of influenza infection or other respiratory 
pathogen by a multiplexed polymerase chain reaction [PCR] test) and symptom diary cards.  
If 3 or more RTI symptoms listed in the table below  occur (at least one must be a respiratory symptom), subjects 
will contact study staff, then collect nasal/throat swab sa mples (the swabs should take  place as soon as possible 
after the start of symptoms, ideally w ithin 48 hours, but no later than 5 da ys). Subjects will complete symptom 
diary cards every 7 days to capture the worst grade of symptoms that occurred during the previous week. The Investigator/study staff will arrange for prompt shipment of the nasal/throat samples to the testing laboratory. 
Note: If the reported symptoms are already of a level of severity that urgent care is indicated, the subject should be directed to the appropriate facility  to receive this care (e.g., emergency room). Otherwise, symptoms should be 
treated according to standard of care. 
If an influenza infection is confirmed by the testing laboratory before the Day 120/165 outpatient visit, the event 
should be documented until all symptoms have resolved, including completion of the symptom diary card every 
7 days. Thereafter, no further RTI surveillance will be carried out on the subject.  
If the nasal/throat swab samples are not confirmed to be influenza by the testing laboratory, diary card 
completion will continue through the Day 120/165 outpatient visit.  
Respiratory Tract Infection (RTI) Symptoms  
x Runny nose (rhinorrhea) x Shortness of breath (dyspnea) 
x Stuffy nose (nasal congestion) x Wheeze 
x Sore throat x Chilliness/feverishness or temperature Â•Â°F 
x Earache x Headache 
x Cough x Body ache 
x Productive phlegm/sputum  
As part of the surveillance, subjects will be questioned during all outpatient site visits for RTI symptoms. If the 
interval to the next outpatient site  visit exceeds 15 days, subjects will be contacted by the Investigator/study staff 
every 2 weeks to query for RTI symptoms. Subjects should be reminded to contact the Investigator/study staff if 
RTI symptoms occur, and to collect the nasal/throat swab samples and complete the symptom diary cards every 7 days. 
Number of Subjects  
A total of 27 subjects will be enrolled in this study;  21 to receive CD388 Injection and 6 to receive placebo.  
Inclusion Criteria  Subjects must meet ALL the following inclusion criteria: 
1. Must be of Japanese descent with Japanese parents and grandparents, as determined by subject's verbal 
report. 
2. Willing and able to provide written informed consent. 
3. Males and females 18 to 65 years of age, inclusive. 
4. A female subject must meet one of the following criteria: 
a. If of childbearing potential â€“ agrees to use a highly effective, preferably user-independent method 
of contraception (failure rate of <1% per year wh en used consistently a nd correctly) for at least 
30 days prior to screening and agrees to remain on a highly effective method until 7 months after 
last dose of study medication. Examples of highly-effective methods of contraception are located in 
Appendix 1 . 
b. If a female of non-childbearing potential â€“ should be surgically sterile (i.e., has undergone complete 
hysterectomy, bilateral oophorectomy, or tubal ligation/occlusion without reversal surgery) or in 
Cidara Therapeutics, Inc.  Protocol CD388.SQ.1.03 
CD388 Injection 
Amendment 1 Confidential  Page 6 of 74 a menopausal state (at least 1 year  without menses), as confirme d by follicle-stimulating hormone 
)6+OHYHOVÂ•P,8P/  
5. A woman of childbearing potential must have a negative highly sensitive serum pregnancy test 
È•-human chorionic gonadotropin) at screening and a negative urine pregnancy test on Day -1 before the 
first dose of study drug. 
6. A woman must agree not to donate eggs (ova, oocytes) for the purposes of assisted reproduction during 
the study and for a period of at least 7 months after study drug administration. 
7. A male subject that engages in sexual activity that has the risk of pregnancy must agree to use a double 
barrier method (e.g., condom and spermicide) and agree not to donate sperm during the study and for at least 7 months after the last dose of the study medication. 
8. Good health and without signs or symptoms of current illness. 
9. Normal clinical examination, including: 
a. No physical examination findings that an Investigator determines would interfere with interpretation 
of study results. 
b. Screening ECG without clinically significant abnormalities (see Appendix 2 ).  
c. &UHDWLQLQHFOHDUDQFH&U&/Â•P/PLQDVFDOFXODWHGXVLQJ the Cockcroft-Gault equation: 
Ü®Ü¥ÝŽÜ¥( = 140àµ†ÝÝƒÜ½ ) Ã— (ÝÝ„ÝƒÝ…ÝÝ“  ÝŠÝ… ÝƒÝ‡)
72 Ã— (Ý‰Ý‘ÝŽÝÝ  ÝÝŠÝ…ÝŠÝ…ÝÜ½ÝÝŽÜ¿  ÝŠÝ… ÝƒÝ‰/Ü®Ý€) Ã— (0.85 Ý‚Ý… ÝÝˆÜ½Ý‰ÝÝ‚)  
d. Negative urine screen for drugs of abuse and alcohol at screening and Day -1. 
10. Body weight Â•50 kg and body mass index between 18.0 and 30.0 kg/m2, inclusive, using the following 
equation: 
Ü«Ü¯Ü¤(= ÝÝ„ÝƒÝ…ÝÝ“  ÝŠÝ… ÝƒÝ‡)
(ÝÝ„ÝƒÝ…ÝÝ„  ÝŠÝ… ÝÝŽÝÝÝÝ‰)à¬¶ 
11. Willing to refrain from strenuous physical activity th at could cause muscle aches or injury, including 
contact sports, at any time from screening through 30 days after any dose of study drug. 
12. Subject has adequate venous access for blood collection. 
Exclusion Criteria 
Subjects must NOT meet any of the following exclusion criteria: 
1. History of any hypersensitivity or allergic reacti on to zanamivir or other neuraminidase inhibitors 
(i.e., laninamivir, oseltamivir, peramivir), or to excipients of the CD388 Injection drug formulation; 
or history of drug-induced exfoliative skin disorders (e.g., Stevens-Johnson syndrome [SJS], erythema 
multiforme, or toxic epidermal necrolysis [TEN]). 
2. History of any of the following: 
a. Allergies, anaphylaxis, skin rashes (foods such as milk, eggs, medications, vaccines, polyethylene 
glycol [PEG], etc.). 
b. Chronic immune-mediated disease, positive first-degree family history of autoimmune diseases. 
c. Atopic dermatitis or psoriasis. 
d. Bleeding disorder. 
e. Psychiatric condition, seizures, hallucinations, anxiety, depression, or treatment for mental 
conditions. 
f. Migraines. 
g. Syncope, or vasovagal syndrome with injections or blood draws. 
h. Cardiac arrythmia considered clinically significant by the Investigator. 
3. Subjects with one or more of the following laboratory abnormalities at screening as defined by the DAIDS Table for Grading the Severity of Adult and Pediatric Adverse Events v2.1 ( DAIDS 2017 ): 
a. 6HUXPFUHDWLQLQH*UDGHÂ•Â•Ã®XSSHUOLPLWRIQRUPDO>8/1@ . 
b. Pancreatic amyl DVHRUOLSDVH*UDGHÂ•Â•Ã®8/1 . 
Cidara Therapeutics, Inc.  Protocol CD388.SQ.1.03 
CD388 Injection 
Amendment 1 Confidential  Page 7 of 74 c. $VSDUWDWHDPLQRWUDQVIHUDVH$67 RUDODQLQHDPLQRWUDQVIHUDVH$/7*UDGHÂ•Â•Ã®8/1 . 
d. 7RWDOELOLUXELQ*UDGHÂ•Â•Ã®8/1 . 
e. $Q\RWKHUWR[LFLW\*UDGHÂ•H[FHSWIRU*UDGHHOHYDWLRQVRIWULJO\FHULGHVORZGHQVL ty lipoprotein 
cholesterol, and/or total cholesterol. 
f. Any other laboratory abnormality considered to be clinically significant by the Investigator. 
Note : Retesting of abnormal laboratory values that ma y lead to exclusion will be allowed once without 
prior asking approval from the Sponsor. Retesting will take place during a scheduled or unscheduled 
visit during screening. Subjects with a normal value at retest may be included. 
4. Alcohol or drug addiction in the past 2 years. 
5. Experiencing symptoms of acute illness or chronic disease within 14 days prior to clinical research unit 
(CRU) check-in.  
6. At screening, a positive result for hepatitis B viru s surface antigen, hepatitis C virus antibody, or human 
immunodeficiency virus (HIV) antibody.  
7. A positive result at CRU check-in for severe acut e respiratory syndrome coronavirus 2 (SARS-CoV-2) 
by polymerase chain reaction (PCR). 
8. Unwilling to comply with local health policy effective at the time regarding coronavirus disease 2019 
(COVID-19). Full COVID-19 vaccination prior to participation is strongly recommended. 
9. Women who are pregnant or nursing. 
10. Received any over-the-counter (OTC ) medications or nutritional suppl ements within 7 days, or any 
prescription medications within 14 days or <5 half-lives prior to dosing, whichever is longest (except for 
hormonal contraceptives, acetaminophen, or ibuprofen). 
11. Current nicotine user or has quit habitual nicotine use in the 30 days prior to screening. 
12. Received any vaccines or immunoglobulins within 28 days prior to dosing (90 days in case of 
intravenous immunoglobulin [IVIg] or biol ogics, or 14 days for COVID-19 vaccine). 
13. Donated blood (within 56 days of screening) or plasma (within 7 days of screening) or experienced 
significant blood loss or significant blood draw (blood donation or blood loss of Â•500 mL) when 
participating in non-interventional clinical trials within 30 days prior to dosing. 
14. Received a blood transfusion within 28 days prior to dosing. 
15. Received any biologics within 90 days prior to dosing; or previous partic ipation in another study 
(including investigational device studies) within 30 days of dosing or 5 half-lives of the study drug, 
whichever is longer, prior to screening (prior pa rticipation at any time in non-invasive methodology 
trials in which no drugs were given is acceptable). 
16. Previous treatment with CD388. 
17. Preplanned surgery at any time during the study. 
18. The Principal Investigator (PI) considers that the volunteer should not participate in the study. 
Test Product, Dose and Mode of Administration  
CD388 Injection is a clear to lightly opalescent liquid essentially free of particulate matter containing the active 
pharmaceutical ingredient, CD388. CD388 Injection is supplied as a frozen st erile solution in single-use vials. 
CD388 Injection is administered by subcutaneous (SQ) injection at 50 mg, 150 mg, or 450 mg (Cohort 1,  Cohort 
2, or Cohort 3, respectively). Dose levels to be assessed will follow an ascending single-dose regimen with the 
starting dose based on findings from 3-month rat and monkey toxicology studies. 
Comparator 
Normal saline will be administered SQ as the placebo control.  
Duration of Treatment 
A single dose of study drug will be administered SQ on Day 1. Study participation will require up to 28 days for 
screening procedures, and ~120/165 days for dosing and follow-up (check-in to the CRU on Day -1; CRU 
inpatient stay for study drug administration, observation, and assessments and procedures for 15 days [Days -1 
to Day 14]; and 5 CRU outpatient visits for additional assessments and procedures). 
Cidara Therapeutics, Inc.  Protocol CD388.SQ.1.03 
CD388 Injection 
Amendment 1 Confidential  Page 8 of 74 Criteria for Evaluation 
Safety and Tolerability of Study Drug Safety and tolerability will be assessed by monitoring AEs (including systemic reactogenicity/injection site 
reactions, hypersensitivity reactions, and AESIs), vital signs, 12-lead ECGs, clinical laboratory results 
(hematology, coagulation, serum chemistry, urinalysis), and concomitant medication usage throughout the study.  
See the Study Design section for details regarding cohort/dose level enrollment timing and assessment of safety 
and tolerability for dose escalation decision. 
If a dose level is considered not safe or well tolerated, the study drug assignment for the subject(s) with the safety 
issue may be unblinded. The Sponsor may also independently decide to unblind the entire cohort for safety 
concerns or terminate enrollment for any reason. 
,IDQ\VXEMHFWGHYHORSVD*UDGHÂ•$( or an SAE of any grade that is deemed related to the study drug, the 
mechanism of the AE may be assessed (i.e., cytokine level, complement activation, immunoglobulin G [IgG] 
subtypes, immunoglobulin E [IgE], T-cell/B-cell/mo nocyte and basophil activation as assessed by flow 
cytometry, ADA development, and immune complex formation) at Sponsor and Investigator discretion, and the 
study dose may be modified for the remainder of the study. 
Pharmacokinetics/Anti-drug Antibodies 
Pharmacokinetics will be determined by analyzing plasma samples for concentration of CD388 obtained from 
subjects who receive CD388 Injection in  each cohort at various time points after administration of study drug. 
Anti-drug antibodies (ADA) will also be measured at selected time points by a validated enzyme-linked 
immunosorbent assay (ELISA) method. 
Pharmacogenomics  
A mandatory pharmacogenomic (DNA) blood sample will be collected once, preferably on Day 1 (collection at 
another time point is permitted if necessary) to allow for genetic research to help understand the characteristics 
of CD388. Genetic analysis will be conducted if it is hypothesized that this may help explore genetic markers that 
could explain differences in safety , immunogenicity, or clinical respons e among subjects. Host DNA assessment 
will be limited to research related to CD388, including  the development of tests/assays related to CD388 
and flu-like disease. 
Analyses of host DNA may be conducted at the Sponsorâ€™s  discretion and reported separately from the study 
report. 
Exploratory Biomarkers  
Blood samples will be collected to allow for the exploration of biomarkers on the assumption that these markers 
could play a role in the response (safety, reactogenicity, immunogenicity) to CD388. 
These samples and remaining material from other samples may be used for further assay optimization/
qualification, biomarkers, or further exploratory analyses. Samples will only be used for research related to influenza virus infection, flu-like disease, and safety , reactogenicity, and immunoge nicity of CD388, including 
the development of tests/assays related to CD388 and influenza. 
Analyses of biomarkers may be conducted at the Sponsorâ€™s discretion and reported separately from the study 
report. 
Withdrawal from Study  
Subjects may be withdrawn from the study for any of the following reasons: 
x Subject is unable or unwilling to continue 
x Subject elects to withdr aw informed consent 
x Adverse event (whether or not related to study drug) that precludes further participation in the study in 
the judgment of an Investigator and/or Sponsor 
x Protocol non-compliance 
x Subject lost to follow-up, or follow-up is not possible 
x The Investigator considers that it is in the subjectâ€™s best interest not to continue participation in the study 
If a subject is removed from the study for any reason, the subject will be followed for resolution of any ongoing 
AE(s). 
Cidara Therapeutics, Inc.  Protocol CD388.SQ.1.03 
CD388 Injection 
Amendment 1 Confidential  Page 9 of 74 Temporary Study Halt for Safety Review 
The study will be temporarily halted, pending review of available data, if any of the following occur:  
x ,IÂ•VXEMHFWVH[SHULHQFHWKHVDPH *UDGH$(HYHQWRUODERUDWR U\DEQRUPDOLW\ZLWKLQGD\VDIWHU
study drug administration, considered attributable to CD388 or cannot be attributed to another cause 
x ,IÂ•VXEMHFWH[SHULHQFHVD*UDGH $(RUODERUDWRU\DEQRUPDOLW \ZLWKLQGD\VDIWHUVWXG\GUXJ
administration, considered attributable to CD388 or cannot be attributed to another cause 
x ,IÂ•VXEMHFWH[SHULHQFHVDQ  SAE irrespective of toxicity grade within 28 days after study drug 
administration, considered attributable to CD388 or cannot be attributed to another cause 
If it is considered appropriate to restart the study following an internal safety review, an amendment, if required, 
will be submitted to the Food and Drug Administration (FDA) and Institu tional Review Board (IRB). The study 
will not restart until the amendment has been approved by the FDA and IRB.  
Statistical Methods  
Safety, tolerability, and PK will be summarized using descriptive statistics. There will be no formal hypothesis 
testing. Analysis populations are: 
x Safety Population: all subjects who receive any amount of study drug 
x PK Analysis Population: all subj ects who receive CD388 Injection and who have any blood samples 
analyzed 
A Statistical Analysis Plan (SAP) will be prepared and finalized before unblinding for the first interim analysis. 
Any deviations from the final SAP will be described and justified in the study report. All statistical analyses will 
be performed using SASÂ®. 
Descriptive statistics, including the numbers and percenta ges for categorical variable s, and the numbers, means, 
standard deviations, medians, minimums, and maximums for continuous variables, will be provided. All data will 
be summarized separately by dose level and study drug (CD388 Injection or placebo). Listings of individual 
subject data will also be produced.  
Safety will be evaluated by presenting summaries of AEs and SAEs, ECGs, clinical laboratory evaluations 
(hematology, coagulation, serum chemistry, urinalysis), and vital signs. Adverse events will be coded using the 
Medical Dictionary for Regulatory Activities (MedDRA). The incidence of TEAEs and AESIs will be presented 
by System Organ Class (SOC) and Preferred Term (PT), relationship to study drug, and severity. A TEAE is 
defined as an AE that emerges during or after study drug administration having been absent pre-treatment, or 
worsens relative to the pre-tr eatment state, and through the final study visi t. In addition, the incidence of serious 
TEAEs and TEAEs leading to discontinuation of study drug or from the study will be presented by SOC and PT. Descriptive statistics for clinical laboratory test re sults, ECG parameters, and vital signs, and for changes from 
Baseline, will be presented by time point. The incidences  of potentially clinically significant (PCS) clinical 
laboratory results, ECG parameters, and vital signs will also be summarized by time point.  
A summary of the injection site evaluation will be presented. The number and percentage of subjects with any 
local reaction will be provided, as will the number and percentage of subjects with pain, tenderness, 
erythema/redness, and induration/swelling. The severity of each local reaction will also be presented. 
The number and percentage of subjects with any RTI will be provided. The PK parameters that will be assessed in the PK Analysis Population include: 
x maximum plasma concentration (C
max) 
x time to maximum plasma concentration (T max) 
x terminal elimination half-life (t Â½) 
x apparent clearance (CL/F) 
x apparent volume of distribution (V Z/F)  
x area under the plasma concentration-time curve from time 0 to time of last quantifiable sample (AUC 0-last) 
x area under the plasma concentration-time curve from time 0 extrapolated to infinity (AUC 0-Â’)  
Analysis of the ADA results is to be determined and may include determination of the subjectâ€™s positive/negative 
ADA status at baseline, treatment-emergent ADA in subjects with a negative baseline, as well as a post-baseline 
increase in titer for subjects with positive ADA at baseline. 
Cidara Therapeutics, Inc.   Protocol CD388.SQ.1.03 
CD388 Injection 
Amendment 1 Confidential  Page 10 of 74 1.1. Schedule of Events 
Table 1: Schedule of Events 
 Screening Clinical Research Unit (CRU) Inpatient Stay Outpatient CRU Visits  
Day 
(Window) -28 to -2 -1 1 2 3â€“6 7 9 11 14 30 
(Â±3) 45 
(Â±3) 60 
(Â±5) 90 
(Â±7) 120/165 a 
(Â±14) 
Informed consent X              
Inclusion/Exclusion criteria  X X             
Medical history/demographics X              
Complete physical with vital signs 
(BP, RR, HR, oral temperature, height, 
weight, BMI)  X              
Targeted physical with vital signs 
(BP, RR, HR, oral temperature, weight b)  X X c X X X   X X X X X X 
Safety ECG d X X X   X   X X    X 
Laboratory evaluations (CBC with platelets, coagulation, serum chemistry, 
lipids, urinalysis) X X  X X 
e X   X X X X X X 
Virology screening (HBV, HCV, HIV) X              
Virology screening (SARS-CoV-2)  X             
Serum/urine pregnancy test f X X        X  X X X 
FSH (if applicable to confirm 
postmenopausal status) X              
Drug/alcohol screen g X X             
Randomization   X            
Dosing of study drug   X            
Reactogenicity/injection site inspection h   X  X  X          
PK sample collection i   X X X X X X X X X X X X 
Pharmacogenomics blood sample j   predose            
Exploratory biomarker samples   predose  X e          
Anti-drug antibodies   predose      X X X X X X 
Nasopharyngeal swab collection k   predose X X X X X X X     
Assess and record AEs l  
Concomitant medications/procedures review 
m  
Cidara Therapeutics, Inc.   Protocol CD388.SQ.1.03 
CD388 Injection 
Amendment 1 Confidential  Page 11 of 74 Abbreviations: AEs = adverse events; BMI = body mass index; BP = blood pressure, CBC = complete blood count; COVID-19 = coronav irus disease 2019; CRU = clinical 
research unit; DAR = drug-antibody ratio; ECG = electrocardiogram; FSH = follicle-stimulating hormone; HBV = hepatitis B virus;  HCV = hepatitis C virus; HIV = human 
immunodeficiency virus; HR = heart rate; hr = hour; ICF = informed consent form; PK = pharmacokinetic; RR = respiration rate; S ARS-CoV-2 = severe acute respiratory 
syndrome coronavirus 2. 
Schedule of Events (continued)  
a. The timing of this visit is Day 120 for Cohort 1 and Day 165 for Cohorts 2 and 3. For subjects who discontinue study early, the  Day 120/165 procedures 
should be performed. 
b. Weight should be measured at each of the outpatient visits (Days 30, 45, 60, 90, 120/165). 
c. On Day 1, the targeted physical examination should be performed predose. Vital signs collection will occur predose, 6 hours pos tdose, and as clinically 
indicated, and will be measured with the subject in a seat ed position for at least 3 minutes prior to measurement.  
d. A triplicate 12-lead ECG is to be performed at screening, at CRU check-in on Day -1, predose (immediately prior to study drug a dministration) and 6 hours 
postdose (Â±10 minutes) on Day 1, and as indicated in the schedule. Subjects are to be resting (at least 5 minutes) and semi-recumbent when ECG is being 
conducted. 
e. Laboratory evaluations (including exploratory biomarker samples) need to be performed once during the Day 3â€“6 interval on Day 4 . 
f. $VHQVLWLYHVHUXPSUHJQDQF\WHVWÈ•á€©KXPDQFKRULRQLFJR nadotropin) is required at screening and Day 120/165 for females of childbearing potential. Urine 
pregnancy test may be performed at all other time points. 
g. Drug and alcohol screen is to be performed during the outpatient visits if vital signs are abnormal (see Appendix 2). 
h. At indicated visits, inspection of administration site and surrounding area will be  performed twice daily (once between approxi mately 2â€“4 hours postdose, 
and once approximately 8â€“12 hours postdose, then twice daily on other indicated study days at least 6 hours apart), with any ab normal findings reported as 
AEs. Reactions will be rated according to the scale provided in Table 5 . 
i. Blood samples for PK analysis will be collected predose (-24 hour window); post-dose at 2, 4, and 12 hours (each Â±10 minute win dow); 24 hours (Â±30 minute 
window); 48 hours (Â±1 hour window); 72, 96, 120 hours (each Â±2 hour window); and in the morning on Days 7, 9, 11, 14. Postdose samples collected at 
outpatient CRU visits at Days 30, 45, 60, 90, and 120/165 have the same windows (i.e., in Â±days) as the visits.  
j. A mandatory pharmacogenomic (DNA) blood sample will be collected once, preferably on Day 1 (co llection at another time point is  allowed if necessary) to 
allow for pharmacogenomic research related to CD388. 
k. Nasopharyngeal swab samples will be collected predose on Day 1, and on Days 2, 5, 7, 9, 11, 14, and 30. 
l. Adverse events (including influenza-like illness which will be test ed for both COVID-19 and flu) will be collected for all subj ects from the time of signing 
the ICF through the final study visit. 
m. Concomitant medication and procedures, including those used to treat an AE, will be recorded from 28 days prior to the CD388 In jection/placebo 
administration until the final study visit.  
 
Cidara Therapeutics, Inc. Protocol CD388.SQ.1.03
CD388 Injection
Amendment 1 Confidential Page 12 of 741.2. Study Schema
Cohort 1a
50 mg single dose
 o
osse
Postdose follow-up thru Day 120 
(CRU inpatient stay thru Day 14)
Cohort 2
150 mg single dose
d fll
 h
Postdose follow-up thru Day 165 
(CRU inpatient stay thru Day 14)
 do
osse
Cohort1
a
15
SQ
N = 27 total â€“  N = 9 per Cohort (7 CD388 Injection : 2 Placebo)
Cohort 3
450 mg single dose
Postdose follow
 up thru Day 165
osse
Postdose follow-up thru Day 165 
(CRU inpatient stay thru Day 14)
Cohort2
il d
 d
45
Dose the 9 subjects in Cohort 1. After 50% of the subjects have completed protocol-specified procedures and assessments for ÑˆÏ­Ï¬ days and the dose is determined 
to be safe and well tolerated, Cohort 2 will be enrolled and randomized. Enrollment of the remaining 50% of Cohort 1 will conti nue while the safety data of the first 
50% of Cohort 1 is being reviewed. Similar processes will be followed for dose escalation from Cohort 2 to Cohort 3. a
Cidara Therapeutics, Inc.  Protocol CD388.SQ.1.03 
CD388 Injection 
Amendment 1 Confidential  Page 13 of 74 2. TABLE OF CONTENTS 
1. PROTOCOL SYNOPSIS .............................................................................................3  
1.1. Schedule of Events .....................................................................................................10  
1.2. Study Schema .............................................................................................................12  
2. TABLE OF CONTENTS ...........................................................................................13  
2.1. LIST OF TABLES ......................................................................................................17  
3. LIST OF ACRONYMS, ABBREVIATIONS, AND DEFINITIONS OF 
TERMS .......................................................................................................................18  
4. BACKGROUND AND RATIONALE .......................................................................21  
4.1. Background .................................................................................................................21  
4.1.1.  Influenza â€“ Prevention and Treatment ........................................................................21  
4.1.2.  CD388 â€“ A Long-Acting Antiviral Fc-Conjugate ......................................................22  
4.1.2.1.  CD388 Nonclinical Studies ........................................................................................22  
4.1.2.2.  CD388 Clinical Studies ..............................................................................................23  
4.2. Summary of Benefits and Risks .................................................................................23  
4.3. Justification of Dose ...................................................................................................24  
4.4. Population to be Studied .............................................................................................25  
4.5. Rationale for Trial Endpoints .....................................................................................25  
4.6. Statement of Compliance ............................................................................................25  
5. STUDY OBJECTIVES AND ENDPOINTS ..............................................................26  
6. STUDY DESIGN .......................................................................................................27  
6.1. Description of the Study .............................................................................................27  
6.2. Criteria for Evaluation ................................................................................................28  
6.2.1.  Safety and Tolerab ility of Study Drug ........................................................................28  
6.2.2.  Pharmacokinetics/Anti-drug Antibodies ....................................................................29  
6.2.3.  Pharmacogenomics .....................................................................................................29  
6.2.4.  Exploratory Biomarkers ..............................................................................................29  
6.3. Number of Subjects ....................................................................................................29  
6.4. Measures Taken to Minimize Bias .............................................................................30  
6.5. Expected Duration of S ubject Participation ...............................................................30  
6.6. Method of Treatment Assi gnment and Blinding ........................................................30  
6.7. Data Review Committee .............................................................................................30  
Cidara Therapeutics, Inc.  Protocol CD388.SQ.1.03 
CD388 Injection 
Amendment 1 Confidential  Page 14 of 74 7. SELECTION, DISCONTINUATION, AND WITHDRAWAL OF 
SUBJECTS .................................................................................................................32  
7.1. Subject Inclusion Criteria ...........................................................................................32  
7.2. Subject Exclusion Criteria ..........................................................................................33  
7.3. Requalification for Entry ............................................................................................35  
7.4. Subject Withdrawal Criteria .......................................................................................35  
7.4.1.  Withdrawal from Study Protocol ................................................................................35  
7.5. Replacement of Subjects .............................................................................................35  
7.6. Temporary Study Halt fo r Safety Review ..................................................................35  
7.7. Study Termination by Sponsor and Termination Criteria ..........................................36  
8. STUDY DRUG ...........................................................................................................37  
8.1. CD388 Injection ..........................................................................................................37  
8.1.1.  Directions for Use .......................................................................................................37  
8.1.2.  Drug Storage ...............................................................................................................37  
8.1.3.  Dose Adjustment ........................................................................................................37  
8.2. Placebo Injection ........................................................................................................37  
8.3. Compliance .................................................................................................................37  
8.4. Breaking the Blind ......................................................................................................37  
8.5. Previous and Concomitant Me dications and Substances ............................................38  
8.6. Accountability Procedures ..........................................................................................38  
8.7. Study Drug Handling and Disposal ............................................................................38  
9. STUDY PROCEDURES ............................................................................................39  
9.1. Medical History ..........................................................................................................39  
9.2. Physical Examinations ................................................................................................39  
9.3. Vital Signs ..................................................................................................................3 9 
9.4. Electrocardiograms .....................................................................................................39  
9.5. Laboratory Evaluations ...............................................................................................39  
9.6. Randomization ............................................................................................................41  
9.7. Pharmacokinetics, Pharm acogenomics, Explorator y Biomarkers, and Anti-
drug Antibodies ..........................................................................................................41  
9.8. Reactogenicity/Injection Site Inspection ....................................................................41  
9.9. Adverse Events ...........................................................................................................42  
9.10.  Prior and Concomitant Medications and Concomitant Procedures ............................42  
Cidara Therapeutics, Inc.  Protocol CD388.SQ.1.03 
CD388 Injection 
Amendment 1 Confidential  Page 15 of 74 10. ASSESSMENT OF EFFICACY ................................................................................43  
11. ASSESSMENT OF SAFETY .....................................................................................44  
11.1.  Safety Para meters .......................................................................................................44  
11.2.  Adverse Events ...........................................................................................................44  
11.3.  Adverse Event Reporting ............................................................................................44  
11.3.1.  Notification of Serious Adverse Events .....................................................................44  
11.3.2.  Notification of Emerging Safety Issues ......................................................................46  
11.4.  Definitions ..................................................................................................................46  
11.4.1.  Adverse Event .............................................................................................................46  
11.4.2.  Suspected Adverse Reaction .......................................................................................46  
11.4.3.  Life-Threatening AE or Life-Threat ening Suspected Adverse Reaction ...................46  
11.4.4.  Serious Adverse Event or Serious Suspected Adverse Reaction ................................47  
11.4.5.  Unexpected AE or Unexpected Suspected Adverse Reaction ....................................47  
11.4.6.  Adverse Events of Special Interest .............................................................................47  
11.4.7.  Emerging Safety Issue ................................................................................................47  
11.4.8.  Urgent Safety Measure ...............................................................................................48  
11.5.  Adverse Event Classification ......................................................................................48  
11.5.1.  Relationship to Study Drug ........................................................................................48  
11.5.2.  Severity ...................................................................................................................... .48 
11.5.3.  Serious Adverse Event ................................................................................................49  
11.6.  Adverse Event Follow Up ..........................................................................................49  
11.7.  Adverse Event Management .......................................................................................49  
11.8.  Risks for Women of Childbearing Potential or Du ring Pregnancy ............................49  
12. STATISTICAL METHODS .......................................................................................50  
12.1.  Analysis Populations ..................................................................................................50  
12.2.  Analysis of Study Population and Subject Characteristics .........................................50  
12.3.  Safety Analyses ..........................................................................................................50  
12.4.  Pharmacokinetic Analyses ..........................................................................................51  
12.5.  Analyses of Pharmacogenomics, E xploratory Biomarkers, and Anti-Drug 
Antibodies ...................................................................................................................5 1 
12.6.  Analyses of Respirator y Tract Infections ...................................................................51  
12.7.  Interim Analysis ..........................................................................................................51  
12.8.  Determination of Study Sample Size ..........................................................................52  
Cidara Therapeutics, Inc.  Protocol CD388.SQ.1.03 
CD388 Injection 
Amendment 1 Confidential  Page 16 of 74 12.9.  Handling of Dropouts and Missing, Unused, and Spurious Data ...............................52  
12.10.  Subject Disposition .....................................................................................................52  
12.11.  Deviation Reporting ....................................................................................................52  
13. INVESTIGATOR REQUIREMENTS .......................................................................53  
13.1.  Protocol Adherence ....................................................................................................53  
13.2.  Electronic Case Report Forms ....................................................................................53  
13.3.  Source Document Maintenance ..................................................................................53  
13.4.  Study Monitoring Requirements .................................................................................53  
13.5.  Study Completion .......................................................................................................53  
14. QUALITY CONTROL AND QUALITY ASSURANCE .........................................55  
15. PROTECTION OF HUMAN SUBJECTS .................................................................56  
15.1.  Informed Consent .......................................................................................................56  
15.2.  IRB/IEC Approval ......................................................................................................56  
16. DATA HANDLING AND RE CORD KEEPING ......................................................57  
16.1.  Direct Access to Source  Data/Documentation ...........................................................57  
16.2.  Study Drug Accountability .........................................................................................57  
16.3.  Retention of Records ..................................................................................................57  
16.4.  Long-term Retention of  Samples for Additiona l Future Research .............................58  
17. FINANCING AND INSURANCE .............................................................................59  
18. PUBLICATION POLICY ..........................................................................................60  
19. REFERENCES ...........................................................................................................61  
20. APPENDICES ............................................................................................................62  
APPENDIX 1.  ACCEPTABLE METHODS OF CONTRACEPTION......................................63  
APPENDIX 2.  ECG AND VITAL SIGN ABNORMALITIES .................................................64  
APPENDIX 3.  DIAGNOSTIC CRITERIA AND MANAGEMENT FOR 
ANAPHYLAXIS ........................................................................................................65  
APPENDIX 4.  RASH MANAGEMENT....................................................................................67  
APPENDIX 5.  VISIT SCHEDULE FOR RASH MANAGEMENT FOR ADULT 
SUBJECTS .................................................................................................................72  
APPENDIX 6.  INVESTIGATOR SIGNATURE .......................................................................74  
 
 
Cidara Therapeutics, Inc.  Protocol CD388.SQ.1.03 
CD388 Injection 
Amendment 1 Confidential  Page 17 of 74 2.1. LIST OF TABLES 
Table 1:  Schedule of Events .....................................................................................................10  
Table 2:  Dose Levels and Safety Margins (Animal-to-Human Dose Ratios) for the 
Proposed CD388 50 mg Dose.....................................................................................24  
Table 3:  Study Design ...............................................................................................................27  
Table 4:  Clinical Laboratory Tests ...........................................................................................40  
Table 5:  Injection Site Evaluation .............................................................................................42  
Table 6:  Table Guidelines for Assessing Relationship of Event to Study Drug .......................48  
Table 7:  Guidelines for Severity Assessments ..........................................................................48  
 
 
Cidara Therapeutics, Inc.  Protocol CD388.SQ.1.03 
CD388 Injection 
Amendment 1 Confidential  Page 18 of 74 3. LIST OF ACRONYMS, ABBREVIATIONS, AND DEFINITIONS 
OF TERMS 
Abbreviation Definition 
ADA anti-drug antibodies 
AE adverse event 
AESI adverse event of special interest 
ALT alanine aminotransferase 
AST aspartate aminotransferase 
AUC area under the plasma concentration-time curve 
AUC 0â€“last area under the plasma (or nasopharyngeal) concentration-time curve from time 0 to 
time of last quantifiable sample 
AUC 0-Â’ area under the plasma concentration-time cu rve from time 0 extrapolated to infinity 
BMI body mass index 
BSA body surface area 
CDC US Centers for Disease Control and Prevention 
CL/F apparent clearance  
Cmax maximum plasma (or nasopharyngeal) concentration 
COVID-19 coronavirus disease 2019 
CrCL creatinine clearance 
CRU clinical research unit 
ECG electrocardiogram 
eCRF electronic case report form 
ELISA enzyme-linked immunosorbent assay 
Fc crystallizable fragment 
FDA Food and Drug Administration 
FIH first-in-human 
FSH follicle-stimulating hormone 
GCP Good Clinical Practice 
GLP Good Laboratory Practice 
HIV human immunodeficiency virus 
ICF informed consent form 
ICH International Council for Harmonisation 
IEC Independent Ethics Committee 
IgE immunoglobulin E 
Cidara Therapeutics, Inc.  Protocol CD388.SQ.1.03 
CD388 Injection 
Amendment 1 Confidential  Page 19 of 74 Abbreviation Definition 
IgG immunoglobulin G 
IgG1 immunoglobulin G1 
IRB Institutional Review Board 
IVIg intravenous immunoglobulin 
MedDRA Medical Dictionary for Regulatory Activities 
NA neuraminidase 
NAI neuraminidase inhibitor 
NCA non-compartmental analysis 
NOAEL no-observed-adverse-effect level 
NP nasopharyngeal 
OTC over-the-counter 
PCR polymerase chain reaction 
PCS potentially clinically significant 
PEG polyethylene glycol 
PI Principal Investigator 
PK pharmacokinetic(s) 
PT Preferred Term 
RBC red blood cell(s) 
RTI respiratory tract infection 
SAE serious adverse event 
SAER Serious Adverse Event Report 
SAP Statistical Analysis Plan 
SARS-CoV-2 severe acute respiratory syndrome coronavirus 2 
SJS Stevens-Johnson syndrome 
SOC System Organ Class 
SOP Standard Operating Procedure 
SQ subcutaneous 
tÂ½ terminal elimination half-life 
TEAE treatment-emergent adverse event 
TEN toxic epidermal necrolysis 
TM targeting molecule 
Tmax time to maximum plasma (or nasopharyngeal) concentration 
Cidara Therapeutics, Inc.  Protocol CD388.SQ.1.03 
CD388 Injection 
Amendment 1 Confidential  Page 20 of 74 Abbreviation Definition 
ULN upper limit of normal 
US United States 
VZ/F apparent volume of distribution 
WBC white blood cell(s) 
 
Cidara Therapeutics, Inc.  Protocol CD388.SQ.1.03 
CD388 Injection 
Amendment 1 Confidential  Page 21 of 74 4. BACKGROUND AND RATIONALE 
4.1. Background 
4.1.1. Influenza â€“ Prevention and Treatment 
Globally, millions are hospitalized each year and about 650,000 deaths occur due to influenza 
(Iuliano 2018 ). In the United States (US), an estima ted 37â€“43 million influenza- related illnesses, 
17â€“  20 million influenza-related medical visits, 500,000 to 650,000 influenza-related 
hospitalizations, and 61,000 deaths occu rred during the 2018â€“2019 influenza season 
(Brammer 2019 ). These numbers remain high year afte r year because currently no effective 
medicine is available for th e prevention of influenza. 
The US Centers for Disease Control and Prev ention (CDC) recommends the administration of 
an influenza vaccine yearly for the prevention of in fluenza, but the efficacy varies yearly due to 
the emergence of new strains. According to the CDC, during the 2018â€“2019 influenza season, 
the vaccine was only 29% effective ( Flannery 2019 ). Vaccines cannot offer complete protection 
because of high genetic diversity  between and within influen za A and B types. Additionally, 
rapid antigenic drift and antigen ic shift in the virus erodes vaccine durability (necessitating 
development of new vaccines annually), and slow vaccine manufac turing cycles make it difficult 
to keep pace with constantly mutating seasonal and pandemic  viral strains. 
The neuraminidase inhibitors (NAIs) oral oseltamivir and inhaled zana mivir are approved for 
prophylaxis and treatment of acute  uncomplicated influenza. Use of NAI antiviral prophylaxis is 
recommended to control instituti onal outbreaks of influenza when used within 48 hours after 
exposure in individuals who are not vaccinated  or who are unlikely to respond to influenza 
vaccines and are immunosuppressed or have co-mor bidities that predispose them to severe 
influenza illness. However, when NAIs are us ed for prophylaxis, even when used promptly 
after a known exposure, the efficacy is  only around 70â€“80% and prolonged use in 
immunocompromised individuals can lead to  the emergence of NAI drug resistance 
(Okoli 2014 ). 
Over the past 20 years there has been increasi ng concern that highly pathogenic avian strains 
such as H7N9 and H7N7 can be transmitted to humans causing high fatality rates in a manner similar to that of the H5N1 pandemic strain in 1997. Although the transmission of these avian 
strains to humans has been largely limited to individuals exposed to poultry, the possibility of 
the emergence of a highly pathogenic and human -adapted influenza variant is concerning 
(Paules 2017). Furthermore, recent modeling predicts that, in the event of a pandemic event 
along the lines of the 1918 Spanish flu, 33 million people would die in the first 6 months before a vaccine could be developed and many millions more would die during the time it would take for the global population to be immunized ( Abbasi 2019 ). 
Progress towards a medicinal agent that provides protection agains t a broad range of influenza 
strains with a longer duration of  protection, otherwise known as a â€œuniversal vaccineâ€, has been 
disappointing. The monoclonal antibody (mAb) therapeutics developed to date have suffered 
from limited spectrum and commercial limitations due to high dosing requirements and/or the need for multiple antibody cocktails to achie ve a desired spectrum and efficacy. Thus, 
a significant unmet need exists for long-acting universal protective agents. 
Cidara Therapeutics, Inc.  Protocol CD388.SQ.1.03 
CD388 Injection 
Amendment 1 Confidential  Page 22 of 74 4.1.2. CD388 â€“ A Long-Acting Antiviral Fc-Conjugate 
Cidara Therapeutics, Inc. (Cidara) is developing a novel therapeutic and prophylactic agent that 
has a potential to provide durable single-dose â€œ universalâ€ coverage per flu season. Cidara has 
replaced variable domains of a monoclonal an tibody with multiple copies of a highly potent 
small molecule antiviral agent (the marketed NAI zanamivir) tailored to target a small, highly 
conserved essential influenza target. This mo lecule, CD388, is a first in class long-acting 
antiviral Fc-conjugate (AVC) combining a surface-acting antiviral agent with the crystallizable 
fragment (Fc) of a human immunoglobulin G1 (IgG1) antibody. 
CD388 differs from traditional antibody-drug conjugate (ADC) molecules in the following 
aspects: 
x In traditional antibody-drug conjugates the dr ug is attached to full length human IgG 
(Fc + antigen-binding fragment [Fab]); in contrast, zanamivir dimers of CD388 are 
conjugated to an Fc fragment of human IgG1 (and not full length IgG1). 
x In traditional antibody-drug conjugates the dr ug is conjugated to the human IgG using 
a protease-cleavable linker to allow release of the drug inside target cells; the linker between zanamivir and the Fc in CD388 is not a substrate for proteases, and it exerts its 
antiviral activity in the extracellular space. 
x Traditional antibody-drug conjugates are used to treat cancer by delivering cytotoxic 
payloads to target cells with rapid rel ease; CD388 is designed to treat and prevent 
infectious disease using a l ong-acting stable conjugate of a non-cytotoxic small molecule 
to an Fc fragment of IgG1 
In nonclinical in vitro and in vivo models, CD388 has demonstrated the potential for significantly higher antiviral activity and efficacy compared to the parent molecule, zanamivir, as well as other NAIs, including oseltamivir. 
4.1.2.1. CD388 Nonclinical Studies 
Several in vitro and in vivo nonc linical studies have been conduc ted to evaluate the safety 
and efficacy of CD388 and/or related Fc-conjuga ted prototype targeting molecules (TMs) to 
support dosing in humans. In vitro NAI and cell- based assays were conducted with CD388 to 
assess its spectrum and potency ag ainst Wild Type (WT) as well as drug-resistant influenza 
strains. In vitro studies to characterize the ex tent of neonatal crystalli zable fragment receptor 
(FcRn) and Fc- È– receptor binding across different species  were conducted. In vitro studies to 
characterize the potential for resistance devel opment with CD388 have be en undertaken. In vivo 
efficacy of CD388 was observed in treatment, and prophylaxis or preventative mouse lethal 
infection models. 
,QYLWURVWDELOLW\RIWKH70FR PSRXQGDORQHZDVTXDQWLWDWLYHO\WHVWHGDWá‚LQSKRVSKDWH -
buffered saline, plasma, and liver microsomes. Stability of the intact Fc-conjugated molecule, 
CD388, was qualitatively observed in liver mi FURVRPHVDWá‚,QYLYRWKHpharmacokinetics 
were investigated in animal species that were used to characterize the pharmacological and toxicological profile of CD 388 and related molecules; namely  in mouse, rat, and monkey. 
More importantly, following pharm acokinetic studies in the mouse, rat, and monkey, plasma 
concentrations were quantified by a neuraminidase (NA)-capture or Fc-capture with Fc detection 
Cidara Therapeutics, Inc.  Protocol CD388.SQ.1.03 
CD388 Injection 
Amendment 1 Confidential  Page 23 of 74 enzyme-linked immunosorbent a ssay (ELISA) methods, to conf irm the stability of CD388 in 
vivo. NA-capture/Fc-detection measures the concentration of intact NA-linked-Fc species while 
Fc-capture/Fc-detection measures the total concentration of Fc-related species. Plasma concentrations measured by both methods were  comparable, suggesting that intact CD388 
remained stable in vivo as designed. 
Single-dose, range-finding intramuscular (IM)  and/or subcutaneous (SQ) toxicity 
and toxicokinetic studies, with endpoint evaluations occurring over the plasma exposure 
periods of 4 weeks in rats and 6 weeks in monkeys, have been conducted. The pivotal Good 
Laboratory Practice (GLP) toxicity studies in clude endpoints to assess safety pharmacology 
(i.e., cardiovascular, respirator y, and neurobehavioral effects) and toxicokinetic s to determine 
safety margins. In addition, screening fo r anti-CD388 antibodies, cytokine analysis, 
and immunophenotyping have been performed. These pivotal GLP nonclinical studies 
supporting first-in-human (FIH) studies were designed in acco rdance with the relevant 
International Council for Harmonisation (ICH) guidance and US Food and Drug Administration 
(FDA) guidance on safety and toxicology studies  for CD388â€™s predecessor molecule (CD377). 
Refer to the Investigatorâ€™s Brochure for additional nonclinical information. 
4.1.2.2. CD388 Clinical Studies 
In an ongoing study (CD388.IM.SQ.1.01), the safe ty and tolerability of CD388 is being 
evaluated in Western healthy adult subj ects, examining CD388 administered either 
intramuscularly or subcutaneously.  
Regular assessment of blinded safety/tolerability data from 33 healthy subjects who received 
a dose of 50 mg, 150 mg, or 450 mg of subcutan eous CD388 or placebo has not identified any 
concerning safety observations to date. 
All treatment-emergent adverse events (TEAEs) have been Grade 1 or Grade 2 (mild or 
moderate) in severity, with headache being the most frequently occurring (27.3% subjects), none 
of which occurred in the higher dose group (150 mg) as of the first Interim Analysis in the FIH 
study. Since then, preliminary safety data generated from the 450 mg dose group indicated that the safety and tolerability profile remained unchanged. 
Of note, as of the first interim analysis in the FIH study, all TEAEs in the higher dose group (150 
mg) have been Grade 1. No serious adverse even ts (SAEs) have occurred, and no drug-related 
TEAEs have resulted in clinically significant hematology or chemistry laboratory abnormalities. 
No safety issues associated w ith electrocardiograms (ECGs), vita l signs, or physical examination 
findings (including local injection site reactions) have been iden tified. No safety findings have 
resulted in discontinuation or study drug or withdrawal from study. Preliminary safety data 
generated from the 450 mg dose group indicated that the safety and tolerability profile remained 
unchanged. 
4.2. Summary of Benefits and Risks 
A brief summary of clinical and nonclinical data is presented in Section 4.1.2. 
The risks for the individual subj ect due to administration of CD 388 Injection are considered low 
and are outweighed by the potential to develop a ne w treatment in an area of high unmet medical 
need. To further minimize any potential risk, all subjects will be closely screened for any 
Cidara Therapeutics, Inc.  Protocol CD388.SQ.1.03 
CD388 Injection 
Amendment 1 Confidential  Page 24 of 74 underlying conditions that may increase risk of study participation. During the conduct of the 
study, subjects are housed in a clinical re search unit (CRU) for 14 days after CD388 
Injection/placebo administration, under continuous medical supervision.  
4.3. Justification of Dose 
The dose(s) planned for this study are based on results obtained from the FIH clinical study, GLP 
3-month exposure toxicology studies  in rats and primate s, and the FDAâ€™s guidance contained in 
â€œEstimating the Maximum Safe Starting Dose in Initial Clinical Trials for Therapeutics in Adult 
Healthy Volunteers â€ (FDA 2005 ). 
From the 3-month GLP toxicology studies in ra ts and monkeys, a no-observed-adverse-effect 
level (NOAEL) of 500 mg/kg has been estab lished for both species. CD388 safety margins 
generated from these pivotal 3-month exposure st udies in support of the dose are presented in 
Table 2 . At the 50 mg human dose administered as a bol us SQ injection, the safety margin based 
on the 3-month NOAELs and using body surface area (BSA) is 97-fold in rats and 194-fold in 
monkeys. Safety margins based on human area under the plasma concentration-time curve 
(AUC) predictions at 50 mg relative to the ra t and monkey 3-month plasma AUC exposures are 
166-fold in rats and 581-fold in monkeys. 
Table 2: Dose Levels and Safety Margins (Animal-to-Human Dose Ratios) for the 
Proposed CD388 50 mg Dose 
3-Month Pivotal 
Toxicity 
Studies c Animal Dose or Plasma Levels 
at NOAEL a Safety Margins for 50 mg Human Dose 
Animal-to-Human Ratios b 
mg/kg mg/m2 d AUC 
(Î¼gÃ—h/mL) e Cmax 
(Î¼g/mL) Based 
on BSA Based on 
Predicted 
Plasma AUC f Based on 
Predicted 
Plasma C max f 
Rat 500 3000 641,000 1190 97-fold 166-fold 83-fold 
Monkey 500 6000 2,240,000 3390 194-fold 581-fold 235-fold 
Abbreviations: AUC = area under the plasma concentration-time curve; AUC 0â€“3month  = area under the plasma concentration-
time curve from time 0 to 3 months; AUC 0-Â’ = area under the plasma concentration-time curve from time 0 extrapolated to 
infinity; BSA = body surface area; C max = maximum plasma concentration; FIH = first-in-human; IM = intramuscular; 
IV = intravenous; NOAEL = no-observed-adverse-effect  level; PK = pharmacokinetic; SQ = subcutaneous. 
a. NOAEL in rat and monkey  3-month studies. 
b. Safety margins based on the proposed FIH dose of 50 mg or 0.833 mg/kg based on a 60 kg person, and 31 mg/m2 based on 
a 1.62 m2 person (FIH Guidance). 
c. Repeat dose NOAEL from pivotal 3-month toxicity studies (NC CD388-004, NC-CD388-003). 
d. The mg/m2 dose was derived by multiplying mg/kg by 6 (rat) or 12 (cynomolgus monkey) (FIH Guidance). 
e. Mean AUC 0â€“3month  values (males and females combined) calculated over 3 months: rat by summing AUC from 3 doses 
and monkey by summing AUC from 2 doses, to cover a 3-month exposure period. 
f. Predicted human plasma PK for 50 mg starting dose (or 0.833 mg/kg based on a 60 kg person): AUC 0-Â’  Â—JÃ®KP/
Cmax = 14.4 Â—g/mL (calculated from 5 mg/kg IV human PK as reported/projected in NC-CD388-05). Note: These 
exposures were predicted for IV administration and would represent the highest values expected as bioavailability from IM 
or SQ administration is anticipated to be approximately 70% of IV based on animal PK studies, potentially lowering the 
exposures in human from IM or SQ dosing. 
 
Safety results of the ongoing clinical tr ial CD388.IM.SQ.1.01 have indicated no significant 
safety findings following single SQ administration of 50, 150 mg, and 450 mg CD388. 
Cidara Therapeutics, Inc.  Protocol CD388.SQ.1.03 
CD388 Injection 
Amendment 1 Confidential  Page 25 of 74 In summary, excellent safety margins were achi eved with CD388 in 3-month toxicity studies 
relative to the FIH human dose conservatively scal ed to BSA and to the predicted FIH plasma 
exposure. Although no adverse findings were identified in nonclinical studies, transient minor 
changes in clinical pathology parameters were  observed in the absence of other changes, 
including no changes in cytokines and microsc opic findings, and no CD388-related effects on 
kidney or the reticuloendothelial system. The out come of the CD388 noncli nical safety program 
supports the proposed clinical program and dos e of 50 mg, 150 mg, and 450 mg administered as 
bolus SQ injections. Results from the FIH st udy to date have shown no significant safety 
findings after 50 mg, 150 mg, and 450 mg CD388 administrations. 
4.4. Population to be Studied 
Healthy adult Japanese subjects. 
4.5. Rationale for Trial Endpoints 
The measures for evaluation of the safety and tole rability profile of CD388 Injection are standard 
for most clinical studies and follow the recommendations in the ICH guidelines. The assessments for determining the plasma concentrations are appropriate to characte rize the pharmacokinetic 
(PK) profile of CD388. 
Exploratory biomarkers, anti-drug antibodies, and pharmacogenomic research are exploratory in 
nature and do not have pre-defined endpoints. 
4.6. Statement of Compliance 
This study will be conducted in compliance with the protocol, International Council for 
Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use 
(ICH) E6 Good Clinical Practice (GCP), and applicable regulatory and IRB requirements. 
Cidara Therapeutics, Inc.  Protocol CD388.SQ.1.03 
CD388 Injection 
Amendment 1 Confidential  Page 26 of 74 5. STUDY OBJECTIVES AND ENDPOINTS 
Objectives Endpoints 
Primary  
x To determine the safety and tolerability 
profile of CD388 Injection when dosed by subcutaneous (SQ) administration as 
a single dose to healthy Japanese adult subjects. x Incidence and severity of treatment-emergent 
adverse events (TEAEs), including but not limited to adverse events (AEs) and serious 
adverse events (SAEs) (including systemic 
reactogenicity/injection site reactions and hypersensitivity reactions), AEs leading to study 
drug discontinuation and/or study withdrawal, 
vital signs, 12-lead electrocardiograms (ECGs), 
and clinical laboratory tests (including 
hematology, coagulation, serum chemistry, 
and urinalysis), after a single dose of CD388. 
Secondary  
x To determine the plasma pharmacokinetic 
(PK) profile of CD388 Injection when 
dosed by SQ administration as a single dose to healthy Japanese adult subjects. x Pharmacokinetic parameters following CD388 
Injection administration: maximum plasma 
concentration (C
max), time to maximum plasma 
concentration (T max), terminal elimination 
half-life (t Â½), apparent clearance (CL/F), 
apparent volume of distribution (V Z/F), area 
under the plasma concentration-time curve from time 0 to time of last quantifiable sample 
(AUC
0-last), area under the plasma concentration-
time curve from time 0 extrapolated to infinity 
(AUC 0-Â’). 
Exploratory 
x To evaluate the PK profile of CD388 in 
upper respiratory tract after SQ administration as a single dose to healthy 
Japanese adult subjects. x Pharmacokinetic parameters following CD388 
Injection administration: maximum nasopharyngeal (NP) concentration (C
max), time 
to maximum NP concentration (T max), area under 
the NP concentration-time curve from time 0 to 
time of last quantifiable sample (AUC 0-last). 
x To evaluate biomarkers that may be 
associated with safety, reactogenicity, and 
immunogenicity after CD388 Injection. x Results of the analyses of exploratory 
biomarkers (including but not limited to 
cytokines, chemokines, acute phase reactants, etc.). 
x To evaluate CD388 immunogenicity. x Anti-drug antibody (ADA) titers in blood (plasma or serum). 
x To explore the effect of CD388 Injection on 
the occurrence of influenza-like illness 
(during flu season). x Occurrence of influenza-like illness reporting 
during the outpatient follow-up period. 
 
Cidara Therapeutics, Inc.  Protocol CD388.SQ.1.03 
CD388 Injection 
Amendment 1 Confidential  Page 27 of 74 6. STUDY DESIGN 
6.1. Description of the Study 
This is a Phase 1, single-center, prospective,  randomized, double-blind study of ascending single 
doses of CD388 Injection administe red SQ to healthy Ja panese adult subjects. The goals are to 
assess safety, tolerab ility, and PK of CD388.  
Subjects will be randomized to re ceive a single dose of CD388 or  placebo administered via SQ 
injection (treatment assignment is blinded) according to the design in Table 3 . 
Table 3: Study Design 
Number of Subjects (N = 27) 
Cohort: dose CD388 
(n = 21) Placebo 
(n = 6) 
Cohort 1: 50 mg 7 2 
Cohort 2: 150 mg 7 2 
Cohort 3: 450 mg 7 2 
Note: A subject may not receive treat ment in more than one cohort. 
After 50% of Cohort 1 subjects have complete d study drug administration and have undergone 
protocol-specified procedures and DVVHVVPHQWVIRUÂ• 10 days, the Principal Investigator (PI) 
and Sponsor will review blinded safety data: AEs (including syst emic reactogeni city/injection 
site reactions, hypersensitivity reactions, and adverse events of special interest [AESIs]), vital 
signs, 12-lead ECGs, and clini cal laboratory results (hematol ogy, coagulation, serum chemistry, 
urinalysis) to determine the safe ty and tolerability of the study drug. The incidence and severity 
of AEs, and any adverse changes in vital signs, clinical laboratory findings, and ECGs will be considered when determining safe ty and tolerability of study drug. If the dose is determined to be 
VDIHDQGZHOOWROHUDWHGÂ• 10 days after dosing, Cohort 2 will be enrolled. Enrollment of the 
remaining 50% of Cohort 1 will con tinue while the safety data of  the first 50% of Cohort 1 is 
being reviewed. Similar proce sses will be followed for dose escalation from Cohort 2 to 
Cohort 3. 
The Schedule of Events is presented in Table 1 . All subjects will be admitted to the clinical 
research unit (CRU) for observati on and safety assessments from Day -1 (check-in) to Day 14. 
Subjects will be monitored for AEs (including systemic reactogenicity/inj ection site reactions, 
hypersensitivity reactions, and AE SIs) and SAEs throughout the study until the final study visit 
after dosing. Safety will also  be assessed by physical exa minations, ECGs, vital signs 
measurements, and laboratory evaluations (hematology, coagulation, serum chemistry, 
urinalysis) at various time points during and after the CRU stay. Concomitant medication use will be recorded throughout the study.  
Blood samples for PK and ADA assessments will be collected throughout the study. To maintain 
the blind, samples will be collected from all subjects; however, only samples from the CD388 
Injection group will be analyzed (using validated  assays) by an unblinded central bioanalytical 
laboratory. Additional blood sample s will be collected for phar macogenomics and exploratory 
biomarker evaluation. 
Cidara Therapeutics, Inc.  Protocol CD388.SQ.1.03 
CD388 Injection 
Amendment 1 Confidential  Page 28 of 74 Respiratory tract infection (RTI) surveillance will be conducted during th e outpatient phase of 
the study from CRU discharge through the Day 12 0/165 outpatient visit or a lab-confirmed 
influenza infection, whichever occurs first. Subj ects will be provided nasal/throat swab kits (for 
detection of influenza infection or other resp iratory pathogen by a multiplexed polymerase chain 
reaction [PCR] test) and symptom diary cards.  
If 3 or more RTI symptoms listed in the table below occur (at least one must be a respiratory 
symptom), subjects will contact study staff, then collect nasal/throat swab  samples (the swabs 
should take place as soon as possible after the start of symptoms, ideally within 48 hours, but no later than 5 days). Subjects will complete symptom diary cards every 7 days to capture the worst grade of symptoms that occurred during the pr evious week. The Investigator/study staff will 
arrange for prompt shipment of the nasal/throat samples to the testing laboratory. Note: If the reported symptoms are already of a level of severity that urgent  care is indicated, the subject 
should be directed to the appr opriate facility to receive th is care (e.g., emergency room). 
Otherwise, symptoms should be treated  according to standard of care. 
If an influenza infection is confirmed by the te sting laboratory before the Day 120/165 outpatient 
visit, the event should be documented until all sy mptoms have resolved, including completion of 
the symptom diary card every 7 days. Thereafter, no further RTI surveillance will be carried out on the subject.  
If the nasal/throat swab samples are not confirmed to be influenza by the testing laboratory, diary 
card completion will continue through the Day 120/165 outpatient visit.  
Respiratory Tract Infection (RTI) Symptoms  
x Runny nose (rhinorrhea) x Shortness of breath (dyspnea) 
x Stuffy nose (nasal congestion) x Wheeze 
x Sore throat x Chilliness/feverishness or temperature Â•Â°F 
x Earache x Headache 
x Cough x Body ache 
x Productive phlegm/sputum  
As part of the surveillance, subjects will be questioned during all outpatient site visits for RTI symptoms. If the interval to the next outpatie nt site visit exceeds 15 days, subjects will be 
contacted by the Investigator/study staff every 2 weeks to query for RTI symptoms. Subjects 
should be reminded to contact the Investigator/study staff if RTI symptoms occur, and to collect the nasal/throat swab samples and complete the symptom diary cards every 7 days.
 
6.2. Criteria for Evaluation 
6.2.1. Safety and Tolerability of Study Drug 
Safety and tolerability will be assessed by monitoring AEs (including systemic reactogenicity/
injection site reactions, hypersensitivity reactions, and AESIs), vital signs, 12-lead ECGs, 
clinical laboratory results (hematology, co agulation, serum che mistry, urinalysis), 
and concomitant medication usage throughout the study.  
See Section  6.1 for details regarding cohort/dose level enrollment timing and assessment of 
safety and tolerability for dose escalation decision. 
Cidara Therapeutics, Inc.  Protocol CD388.SQ.1.03 
CD388 Injection 
Amendment 1 Confidential  Page 29 of 74 If a dose level is considered not safe or we ll tolerated, the study drug assignment for the 
subject(s) with the safety issue may be unblinded. The Sponsor may also independently decide to 
unblind the entire cohort for safety concerns or terminate enrollment for any reason. 
,IDQ\VXEMHFWGHYHORSVD*UDGHÂ•$( or an SAE of any grade that is deemed related to the 
study drug, the mechanism of the AE may be assessed (i.e., cytokine level, complement 
activation, immunoglobulin G [IgG] subtypes, im munoglobulin E [IgE], T-cell/B-cell/monocyte 
and basophil activation as asse ssed by flow cytometry, ADA deve lopment, and immune complex 
formation) at Sponsor and Inve stigator discretion, and the study dose may be modified for the 
remainder of the study. 
6.2.2. Pharmacokinetics/Anti-drug Antibodies 
Pharmacokinetics will be determined by analyzing plasma sa mples for concentration of CD388 
obtained from subjects who receive CD388 Injection in each cohort at various time points after 
administration of study drug. Anti-drug antibodies will also be measured at selected time points 
by a validated ELISA method. 
6.2.3. Pharmacogenomics 
A mandatory pharmacogenomic (DNA) blood sample  will be collected once, preferably on 
Day 1 (collection at another time point is permitted if necessary) to  allow for genetic research to 
help understand the characteristics of CD388. Gene tic analysis will be conducted if it is 
hypothesized that doing so may aid in exploring ge netic markers which could explain differences 
in safety, immunogenicity, or c linical response among subjects. Host DNA assessment will be 
limited to research related to CD388, including the development of tests/assays related to CD388 
and flu-like disease. 
Analyses of host DNA may be conducted at the Sponsorâ€™s discretion a nd reported separately 
from the study report. 
6.2.4. Exploratory Biomarkers 
Blood samples will be collected to allow for th e exploration of biomarkers on the assumption 
that these markers could play a role in the response (safety, reactogeni city, immunogenicity) to 
CD388. 
These samples and remaining material from ot her samples may be used for further assay 
optimization/qualification, biomarke rs, or further exploratory an alyses. Samples will only be 
used for research related to influenza virus infe ction, flu-like disease, and safety, reactogenicity, 
and immunogenicity of CD388, incl uding the development of tests/assays related to CD388 
and influenza. 
Analyses of biomarkers may be conducted at the Sponsorâ€™s discretion and reported separately 
from the study report. 
6.3. Number of Subjects 
A total of 27 healthy volunteers w ill be enrolled in this study in 3 cohorts: 9 of the 27 subjects 
will be enrolled in the first c ohort and randomized in a 7:2 ratio to receive either 50 mg CD388 
SQ injection or matching placebo injection; the remaining subjects will be enrolled in the second 
Cidara Therapeutics, Inc.  Protocol CD388.SQ.1.03 
CD388 Injection 
Amendment 1 Confidential  Page 30 of 74 and third cohorts (9 subjects each) and randomized in a 7:2 ratio to receive either 150 mg 
(Cohort 2) or 450 mg (Cohort 3) CD388 SQ injection or matching placebo injection.  
6.4. Measures Taken to Minimize Bias 
Study drug assignment (CD388 Injecti on or placebo) will be blinded to all blinded clinical site 
and Sponsor study team until at l east after the final subject in a cohort has completed the Day 90 
visit. Unblinded personnel include  the site pharmacist (or pharmacist designee) preparing the 
injections, the unblinded pharmacy monitor (to ensure study drug accountability and assignment throughout the trial), and the Sponsorâ€™s unblinded team. 
6.5. Expected Duration of Subject Participation 
A single dose of study drug will be administered SQ on Day 1. Study partic ipation will require 
up to 28 days for screening procedures, and approximately 120/165 days for dosing and follow-
up (check-in to the CRU on Day -1; CRU inpatient stay for study drug administration, observation, and assessments and procedures for 15 days [Days -1 to Day 14]; and 5 CRU 
outpatient visits for additional assessments and procedures). 
6.6. Method of Treatment Assignment and Blinding 
After informed consent has been obtained, subjects will be screened for study eligibility before randomization. 
Within each dose level (Cohorts 1, 2, and 3), subj ects will be randomized to receive a single dose 
of CD388 Injection or saline placebo (treatment assignment is  blinded). The study siteâ€™s 
pharmacist (or pharmacist desi gnee) will obtain a computer-gen erated study drug assignment. 
A subject is considered randomized when a rando mization transaction is appropriately recorded. 
Unless a formal interim analysis is conducted after all subjects have completed the Day 90 visit, 
all blinded study personnel (including the Sponsor , Investigator, and site personnel directly 
involved in study conduct) and s ubjects will remain blinded to study drug assignment until the 
study is completed and the final database is locked with the exception of the unblinded pharmacy 
personnel, pharmacy monitor, and unblinded Sponsor personnel (such as Data Review 
Committee, clinical supply manager, PK lead, and quality manager) who may be unblinded to 
study medication at any time dur ing study conduct. The pharmacy monitor will monitor study 
drug preparation and accountability during the stu dy and cases in which unblinding is required 
due to a safety or tolerability issue. To ma intain study blinding, study drug preparation will be 
performed by an unblinded site pharmacist (or qua lified unblinded personnel at the study site not 
involved with study procedures or evaluations). Any unblinding related to an interim analysis 
will be documented in the blinding plan. Instructions for study drug preparation and dosing are outlined in the Pharmacy Manual provided 
separately to the site. In the event of a medical  emergency requiring the Investigator to know the 
identity of the study drug, the Investigator will follow the procedures outlined in Section 8.4 . 
6.7. Data Review Committee 
A Sponsor Data Review Committee, consisting of re presentatives of the Sponsor not involved in 
day-to-day management of the study, may be established to re view unblinded data to allow 
Cidara Therapeutics, Inc.  Protocol CD388.SQ.1.03 
CD388 Injection 
Amendment 1 Confidential  Page 31 of 74 strategic development decisions within and acros s development programs. The procedures of the 
Data Review Committee will be documented in a charter. 
Cidara Therapeutics, Inc.  Protocol CD388.SQ.1.03 
CD388 Injection 
Amendment 1 Confidential  Page 32 of 74 7. SELECTION, DISCONTINUATION, AND WITHDRAWAL OF 
SUBJECTS 
7.1. Subject Inclusion Criteria 
Subjects must meet ALL the following inclusion criteria: 
1. Must be of Japanese descent with Japanese parents and gr andparents, as determined by 
subject's verbal report. 
2. Willing and able to provide written informed consent. 
3. Males and females 18 to 65 y ears of age, inclusive. 
4. A female subject must meet one of the following criteria: 
a. If of childbearing potential â€“ agrees to  use a highly effective, preferably 
user-independent method of contraception (fa ilure rate of <1% per year when used 
consistently and correctly) for at least 30 days  prior to screening and agrees to remain 
on a highly effective method until 7 months  after last dose of study medication. 
Examples of highly-effective methods  of contraception are located in Appendix 1.  
b. If a female of non-childbearing potential â€“ should be surgically sterile (i.e., has 
undergone complete hysterectomy, bilateral oophorectomy, or tubal 
ligation/occlusion  without reversal surgery) or in a menopausal state (at least 1 year 
without menses), as confirmed by fo llicle-stimulating horm one (FSH) levels 
Â• mIU/mL). 
5. A woman of childbearing potential must have a negative highly sensitive serum 
SUHJQDQF\WHVWÈ• -human chorionic gonadotropin) at screening and a negative urine 
pregnancy test on Day -1 befo re the first dose of study drug. 
6. A woman must agree not to donate eggs (ova, oocytes) for the purposes of assisted reproduction during the study and for a period of at least 7 months after study drug 
administration. 
7. A male subject that engages in sexual activity th at has the risk of pregnancy must agree to 
use a double barrier method (e.g., condom and sp ermicide) and agree not to donate sperm 
during the study and for at least 7 months af ter the last dose of the study medication. 
8. Good health and without signs or  symptoms of current illness. 
9. Normal clinical examination, including: 
a. No physical examination findings that an Investigator determin es would interfere 
with interpretation of study results. 
b. Screening ECG without clinically significant abnormalities (see Appendix 2).  
c. Creatinine clearance (CrCL) Â•mL/min as calculated using the Cockcroft-Gault 
equation: 
Ü®Ü¥ÝŽÜ¥( = 140àµ†ÝÝƒÜ½ ) Ã— (ÝÝ„ÝƒÝ…ÝÝ“  ÝŠÝ… ÝƒÝ‡)
72 Ã— (Ý‰Ý‘ÝŽÝÝ  ÝÝŠÝ…ÝŠÝ…ÝÜ½ÝÝŽÜ¿  ÝŠÝ… ÝƒÝ‰/Ü®Ý€) Ã—( 0 . 8 5  Ý‚Ý… ÝÝˆÜ½Ý‰ÝÝ‚)  
Cidara Therapeutics, Inc.  Protocol CD388.SQ.1.03 
CD388 Injection 
Amendment 1 Confidential  Page 33 of 74 d. Negative urine screen for drugs of abus e and alcohol at screening and Day -1. 
10. Body weight Â• 50 kg and body mass index between 18.0 and 30.0 kg/m2, inclusive, using 
the following equation: 
Ü«Ü¯Ü¤(= ÝÝ„ÝƒÝ…ÝÝ“  ÝŠÝ… ÝƒÝ‡)
(ÝÝ„ÝƒÝ…ÝÝ„  ÝŠÝ… ÝÝŽÝÝÝÝ‰) à¬¶ 
11. Willing to refrain from strenuous physical activity that could cause muscle aches 
or injury, including contact sports, at any time from screening thr ough 30 days after any 
dose of study drug. 
12. Subject has adequate venous access for blood collection. 
7.2. Subject Exclusion Criteria 
Subjects must NOT meet any of the following exclusion criteria: 
1. History of any hypersensitivity or allergic reaction to zana mivir or other neuraminidase 
inhibitors (i.e., laninamivir, oseltamivir, peramivir), or to excipients of the CD388 
Injection drug formulation; or history of  drug-induced exfoliative skin disorders 
(e.g., Stevens-Johnson syndrome [SJS], eryt hema multiforme, or  toxic epidermal 
necrolysis [TEN]). 
2. History of any of the following: 
a. Allergies, anaphylaxis, skin rashes (foods such as milk, eggs, medications, vaccines, 
polyethylene glycol  [PEG], etc.). 
b. Chronic immune-mediated disease, positive first-degree family history of 
autoimmune diseases. 
c. Atopic dermatitis or psoriasis. 
d. Bleeding disorder. 
e. Psychiatric condition, seizures , hallucinations, anxiety, de pression, or treatment for 
mental conditions. 
f. Migraines. 
g. Syncope, or vasovagal syndrome w ith injections or blood draws. 
h. Cardiac arrythmia considered clinically significant by the Investigator. 
3. Subjects with one or more of the followi ng laboratory abnormalitie s at screening as 
defined by the DAIDS Table for Grading the Severity of Adult and Pediatric Adverse 
Events v2.1 ( DAIDS 2017): 
a. 6HUXPFUHDWLQLQH*UDGHÂ• Â•Ã®XSSHUOLPLWRIQRUPDO>8/1@ . 
b. 3DQFUHDWLFDP\OD VHRUOLSDVH*UDGHÂ•Â•Ã®8/1 . 
c. $VSDUWDWHDPLQRWUDQVIH UDVH$67RUDODQLQH DPLQRWUDQVIHUDVH$ /7*UDGHÂ•
Â•Ã®8/1 . 
d. 7RWDOELOLUXELQ*UDGHÂ•Â•Ã®8/1 . 
Cidara Therapeutics, Inc.  Protocol CD388.SQ.1.03 
CD388 Injection 
Amendment 1 Confidential  Page 34 of 74 e. $Q\RWKHUWR[LFLW\*UDGHÂ•H[ FHSWIRU*UDGHHOHYDWLRQVRIW ULJO\FHUides, low 
density lipoprotein cholesterol,  and/or total cholesterol. 
f. Any other laboratory abnormality considered to be clinically significant by the 
Investigator. 
Note : Retesting of abnorma l laboratory values that may lead  to exclusion will be allowed 
once without prior asking approval from the S ponsor. Retesting will take place during a 
scheduled or unscheduled visit during screen ing. Subjects with a normal value at retest 
may be included. 
4. Alcohol or drug addiction in the past 2 years. 
5. Experiencing symptoms of acute illness or chronic disease within 14 days prior to clinical research unit (CRU) check-in. 
6. At screening, a positive result for hepatitis B virus surface antigen, hepatitis C virus 
antibody, or human immunodeficiency virus (HIV) antibody. 
7. A positive result at CRU check-in for severe acute respiratory syndrome coronavirus 2 
(SARS-CoV-2) by polymeras e chain reaction (PCR). 
8. Unwilling to comply with local health policy effective at the time regarding coronavirus 
disease 2019 (COVID-19). Full COVID-19 vaccina tion prior to partic ipation is strongly 
recommended. 
9. Women who are pregnant or nursing. 
10. Received any over-the-counter (OTC) medications or nutritional supplements within 
7 days, or any prescription medications within 14 days or <5 half-lives prior to dosing, 
whichever is longest (except for hormonal contraceptives, acetaminophen, or ibuprofen). 
11. Current nicotine user or has quit habitual nico tine use in the 30 days prior to screening. 
12. Received any vaccines or immunoglobulins within 28 days prior to dosing (90 days in case of intravenous immunoglobulin [IVIg] or biologics, or 14 days for COVID-19 vaccine). 
13. Donated blood (within 56 days of  screening) or plasma (within 7 days of screening) 
or experienced significant blood loss or significant blood draw (blood donation or blood 
loss of Â• 500 mL) when participating in non-interven tional clinical trials within 30 days 
prior to dosing. 
14. Received a blood transfusion within 28 days prior to dosing. 
15. Received any biologics within 90 days prior to dosing; or previous participation in 
another study (including investigational device studies) within 30 days of dosing or 5 half-lives of the study drug, whicheve r is longer, prior to screening (prior 
participation at any time in non-invasive methodology tr ials in which no drugs were 
given is acceptable). 
16. Previous treatment with CD388. 
17. Preplanned surgery at any time during the study. 
Cidara Therapeutics, Inc.  Protocol CD388.SQ.1.03 
CD388 Injection 
Amendment 1 Confidential  Page 35 of 74 18. The Principal Investigator (PI) considers that  the volunteer should not participate in the 
study. 
7.3. Requalification for Entry 
Subjects not fulfilling the entry criteria and not randomized may be rescreened for participation 
with the approval of the Sponsor Medical Monito r. A subject who rescr eens will receive a new 
screening number. 
7.4. Subject Withdrawal Criteria 
7.4.1. Withdrawal from Study Protocol 
Subjects may withdraw consent to participate in this study at any time without penalty or loss of 
benefits to which the subject is otherwise entitled. Subjects who wish to withdraw completely from this clinical study should be encouraged to  complete the Day 120/165 assessments. Every 
reasonable effort should be ma de to determine the reason a subject withdraws prematurely, 
and this information should be recorded on the ap propriate page(s) of the electronic case report 
form (eCRF). 
Subjects may be withdrawn from the study for any of the following reasons: 
x Subject is unable or unwilling to continue 
x Subject elects to withdr aw informed consent 
x Adverse event (whether or not related to st udy drug) that precludes further participation 
in the study in the judgment of an Investigator and/or Sponsor 
x Protocol non-compliance 
x Subject lost to follow-up, or follow-up is not possible 
x The Investigator considers that it is in th e subjectâ€™s best interest not to continue 
participation in the study 
If a subject is removed from the study for any reason, the subject will be followed for resolution 
of any ongoing AE(s). 
7.5. Replacement of Subjects 
Subjects who are withdrawn for reasons other than AEs may be replaced at the discretion of the Sponsor into the same cohort and blinded treatment assignment as the replaced subject. 
7.6. Temporary Study Halt for Safety Review 
The study will be temporarily halte d, pending review of available data, if any of the following 
occur:  
x ,IÂ•VXEMHFWVH[SHULHQFHWKHVDP H*UDGH$(HYHQWRUODERUDWR ry abnormality within 
28 days after study drug administration, consid ered attributable to  CD388 or cannot be 
attributed to another cause 
Cidara Therapeutics, Inc.  Protocol CD388.SQ.1.03 
CD388 Injection 
Amendment 1 Confidential  Page 36 of 74 x ,IÂ•VXEMHFWH[SHULHQFHVD*UD GH$(RUODERUDWRU\DEQRUPDOLW \ZLWKLQGD\VDIWHU
study drug administration, consider ed attributable to CD388 or  cannot be attributed to 
another cause 
x ,IÂ•VXEMHFWH[SHULHQFHVDQ6$( irrespective of toxicity grad e within 28 days after study 
drug administration, considered attributable to CD388 or cannot  be attributed to another 
cause 
If it is considered appropriate to restart th e study following an internal safety review, 
an amendment, if required, will be submitted to the FDA and IRB. The study will not restart until 
the amendment has been approved by the FDA and IRB. 
7.7. Study Termination by Sponsor and Termination Criteria 
The Sponsor reserves the right to terminate an investigational site or th is clinical study at any 
time. Reasons for termination may include, but are not limited to, the following: 
x The incidence or severity of AEs indicat e a potential health hazard to subjects. 
x Serious or persistent noncompliance by the In vestigator with the protocol, clinical 
research agreement, or applicable re gulatory guidelines in conducting the study. 
x Institutional Review Board (IRB)/Independent Ethics Committee (IEC) decision to 
terminate or suspend approval for the investigation or the Investigator. 
x Investigator request to withdraw from participation. 
x Subject enrollment is unsatisfactory. 
Cidara Therapeutics, Inc.  Protocol CD388.SQ.1.03 
CD388 Injection 
Amendment 1 Confidential  Page 37 of 74 8. STUDY DRUG 
8.1. CD388 Injection 
CD388 Injection is a clear to lightly opalescent liquid essentially free of particulate matter 
containing the active pharmaceutical  ingredient, CD388. CD388 Injection is supplied as a frozen 
sterile solution in single-use vials. Refer to the Pharmacy Manual for details. 
CD388 Injection is administered by SQ injection at the doses described in  Table 3 . Dose levels 
to be assessed will follow an ascending single-dose regimen with the starting dose based on 
findings from 3-month rat a nd monkey toxicology studies. 
8.1.1. Directions for Use 
CD388 Injection should be thawed at room temper ature over 30 minutes (not to exceed 24 hours) 
prior to drawing the dose from the vial into the syringe. 
After CD388 Injection is drawn from the vial in to the syringe, it must be administered within 
4 hours. 
8.1.2. Drug Storage 
Vials of CD388 Injection are stored frozen at -20Â°C. 8.1.3. Dose Adjustment 
Dosage adjustments of CD388 Injection in individual subjects are not allowed in this study. 
8.2. Placebo Injection 
Normal saline will be administered SQ as the placebo control. 
8.3. Compliance 
Treatment compliance for CD388 Injection/pl acebo will be documented in the eCRF by 
recording the date, administration time, and the volume of the dose of study drug administered. 
8.4. Breaking the Blind 
The study is a double-blind design. The Sponsor, Inve stigator, study site personnel, and subjects 
will not make any effort to determine which blinded study drug (C D388 Injection or placebo) is 
administered. Unblinded pharmacy personnel will be responsible for preparing syringes such that 
the double-blind is maintained. 
Only in the case of an emergency, when knowledge of the study drug is essential for the clinical 
management or welfare of a specific subject, ma y the Investigator unblind a subjectâ€™s study drug 
assignment. As soon as possible and without revealing the subjectâ€™s study drug assignment (unless important 
to the safety of subjects remaining in the study), the Investigator must notify the Sponsor if the 
blind is broken for any reason. The Investigator will record in source documentation the date 
and reason for revealing the blinded study drug assignment for that subject. 
Cidara Therapeutics, Inc.  Protocol CD388.SQ.1.03 
CD388 Injection 
Amendment 1 Confidential  Page 38 of 74 As PK samples from subjects assigned to placebo treatment will not be analyzed for 
determination of CD388 concen trations, the bioanalytical laboratory will receive the 
randomization list to allow for correct selection of the samples. Unblinding of the randomized 
treatment assignment will be performed at the bioanalytical laboratory. Specific procedures will 
be in place to ensure that randomized treatme nt assignment will not be revealed to anyone 
involved in the execution of the study. 
8.5. Previous and Concomitant Medications and Substances 
All medications administered within 28 days prior to study drug admin istration and throughout 
the study will be documented and recorded in the eCRF. 
Subjects must refrain from OTC, herbal medications, and nutritional supplements within 7 days 
and prescription medications within 14 days or <5 half-lives before first study drug 
administration, and until after the final study visit (except for hormonal contraceptives, 
acetaminophen, or ibuprofen). The Investigator should consult the Sponsorâ€™s Medical Monitor 
for guidance regarding other medication or vaccine usage during the study. 
8.6. Accountability Procedures 
The pharmacy or study personnel are responsible for ensuring that a current record of CD388 
Injection inventory and acc ountability are maintained.  
A Pharmacy Monitor will be responsible for checking drug accountability at the site. Inventory records must be readily available for inspection by regulatory authorities at any time. 
Each shipment of study drug will require acknow ledgment of receipt. Upon receipt of study 
drug, the pharmacy or study personne l will visually inspect the shipment and verify the number 
and condition of vials received. Refer to th e Pharmacy Manual for additional information. 
8.7. Study Drug Handling and Disposal 
Unless expressly disallo wed by institution rules or local regulations, used and unused vials 
of CD388 Injection will be retained at the study site until study drug accountability has been 
performed by the Pharmacy Monitor. Upon comp letion of the study, termination of the study, 
or upon written authorization from the Sponsor, all retained unused and partially used study drug 
will be centrally destroyed or  destroyed at the site upon wr itten authorization from Sponsor, 
unless expressly disallowed by local  regulations. Adequate docume ntation to support destruction 
is required prior to destruction of the vials, and a certificate of destruction or written 
documentation that specifies the date, quantity, lo t numbers, and method of destruction that is 
traceable to the study drug must be provided to  the Sponsor. All records of disposal will be 
maintained by the Sponsor. 
Cidara Therapeutics, Inc.  Protocol CD388.SQ.1.03 
CD388 Injection 
Amendment 1 Confidential  Page 39 of 74 9. STUDY PROCEDURES 
The Schedule of Events ( Table 1 ) summarizes the frequency and timing of all applicable study 
assessments, including allowable windows for stu dy visits and assessme nts/procedures. Written 
informed consent must be obtained before any study-related procedures are performed. 
All procedures should be completed as close to the prescribed/scheduled time as possible. 
Any nonscheduled procedures required for urgent evaluation of safety concerns take precedence 
over all routine scheduled procedures. 
When multiple assessments are scheduled at the same time point, perform the assessments in the 
following order: 12-lead ECG, vital signs, and blood sample collection.  
9.1. Medical History 
A complete medical history will be recorded, including demographic information (age, gender, race, and ethnicity).  
9.2. Physical Examinations 
A complete physical examination is required at screening. Targeted (i.e., symptom directed) physical examinations may be perfor med at all other indicated visits , and as clinica lly indicated. 
9.3. Vital Signs 
Vital signs include blood pressure (systolic and diastolic), heart ra te, respiration rate, and oral 
temperature, and will be measured with the subject in a seated position for at least 3 minutes prior to measurement. Height and weight are to be measured and body mass index (BMI) calculated when indicated. 
9.4. Electrocardiograms 
Subjects should be resting (at l east 5 minutes) and semi-recumbent for safety triplicate 12-lead 
ECGs. Data collection includes abnormal findings; if abnormal finding(s) are assessed as 
clinically significant, the finding(s)  should be reported as AE(s). The Investigator is responsible 
for interpreting and measuring ECG data. 
The screening ECG may be repeated once to confirm eligibility. 
9.5. Laboratory Evaluations 
Blood and urine for laboratory evaluations will be  collected and analyzed at a laboratory in 
accordance with quality laboratory standards.  Hematology, serum ch emistry, coagulation, 
urinalysis, and other parameters  to be tested are listed in Table 4 . 
Cidara Therapeutics, Inc.  Protocol CD388.SQ.1.03 
CD388 Injection 
Amendment 1 Confidential  Page 40 of 74 Table 4: Clinical Laboratory Tests 
Test Category Specific Laboratory Tests  
Hematology: a Hemoglobin Neutrophils (absolute) 
Hematocrit Monocytes (absolute) 
Erythrocyte (red blood count [RBC]) count Eosinophils (absolute) 
Quantitative platelet count Lymphocytes (absolute) 
Total leukocyte (white blood cell [WBC]) 
count Basophils (absolute) 
Mean corpuscular hemoglobin (MCH) Mean corpuscular volume (MCV) 
Serum 
Chemistry: a Aspartate aminotransferase (AST) Calcium 
Alanine aminotransferase (ALT) CO 2 or bicarbonate 
Alkaline phosphatase (ALP) Blood urea nitrogen (BUN) or urea 
Albumin Creatinine 
7RWDOELOLUXELQLIWRWDOELOLUXELQLVÂ•Ã®
ULN with no evidence of Gilbertâ€™s 
syndrome, then fractionate into direct and 
indirect bilirubin) Glucose 
Sodium Chloride 
Potassium Lipase 
Total protein Lactate dehydrogenase (LDH) 
Phosphorus Amylase 
Creatinine Clearance (Cockcroft-Gault)  
Lipids: b Triglycerides Low Density Lipoproteins (LDL) 
Cholesterol, Total  
Coagulation: b Activated partial thromboplastin time 
(aPTT) International normalized ratio for prothrombin time (INR/PT) 
Complement 
Activation: b Complement C3, C4, CH50  
Urinalysis: a pH Occult blood 
Protein Specific gravity 
Glucose Ketones 
Appearance Color 
Bilirubin Leukocyte esterase 
Nitrite Microscopic reflex if protein, nitrite, blood 
or leukocyte esterase are positive (WBC, 
RBC, epithelial cells, bacteria, casts, other 
findings) 
Serology: Hepatitis B surface antigen (HBsAg) c Human immunodeficiency virus (HIV) 
antibody c 
Hepatitis C antibody c Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) polymerase chain reaction 
(PCR) 
d 
Cidara Therapeutics, Inc.  Protocol CD388.SQ.1.03 
CD388 Injection 
Amendment 1 Confidential  Page 41 of 74 Pregnancy: e Serum beta human chorionic gonadotropin 
È•-hCG) pregnancy test for females of 
childbearing potential (screening and Day 120/165 only), urine or serum test at all other specified visits Follicle-stimulating hormone (FSH), if 
applicable to confirm postmenopausal status, is only required once 
Other: f Drug (opioids, benzodiazepines, barbiturates, cocaine metabolites, cannabinoids, methamphetamines, phencyclidine, amphet amine, cotinine) and alcohol screen 
a. At each visit indicated in the Schedule of Events ( Table 1 ). 
b. Performed at screening, and as clinically indicated (e.g., if the Investigator has concerns regarding an SAE, anti-drug 
antibody reaction in a subject with hypersensitivity reaction, fever, serious rash, joint/bone pain, cough, proteinuria, 
or clinically meaningful changes in the white cell differential or liver function tests). 
c. At screening only. 
d. If a subject develops signs and symptoms of an acute respiratory tract infection at any time during the study, COVID-19, influenza, and/or respiratory syncytia l virus (RSV), nasopharyngeal rapid anti gen test plus PCR will be performed. 
e. As indicated. 
f. At screening and Day -1, and during the outpatient visits if vital signs are abnormal. 
9.6. Randomization 
For randomization procedures, see Section  6.6. 
9.7. Pharmacokinetics, Pharmacogenomics, Exploratory Biomarkers, 
and Anti-drug Antibodies 
Blood and NP swab samples for pharmacokinetic analysis, pharmacogenomics, exploratory 
biomarkers, and anti-drug antibodi es will be collected as indicat ed in the Schedule of Events 
(Table 1 ). Refer to the laboratory manual for instructions on collection of these samples for 
analysis. 
Refer to the laboratory manual for instructions on collection of samp les from nasopharyngeal 
swab for exploratory CD388 assays.  
9.8. Reactogenicity/Injection Site Inspection 
At indicated visits, inspection of administra tion site and surrounding area will be performed 
twice daily, with any abnormal findings reported as AEs. Reactions will be rated according to 
Table 5 . 
Cidara Therapeutics, Inc.  Protocol CD388.SQ.1.03 
CD388 Injection 
Amendment 1 Confidential  Page 42 of 74 Table 5: Injection Site Evaluation 
Local Reaction Mild 
(Grade 1) Moderate 
(Grade 2) Severe 
(Grade 3) Potentially Life 
Threatening 
(Grade 4) 
Pain Does not interfere 
with activity Repeated use of 
non-narcotic pain 
reliever >24 hours or 
interferes with 
activity Any use of narcotic 
pain reliever or 
prevents daily activity Emergency room (ER) 
visit or hospitalization 
Tenderness Mild discomfort to 
touch Discomfort with 
movement Significant discomfort 
at rest ER visit or 
hospitalization 
Erythema/Redness a 2.5â€“5 cm 5.1â€“10 cm >10 cm Necrosis or 
exfoliative dermatitis 
Induration/Swelling b 2.5â€“5 cm and does 
not interfere with 
activity 5.1â€“10 cm or 
interferes with 
activity >10 cm or prevents 
daily activity Necrosis 
a. In addition to grading the measured local reaction at the grea test single diameter, the measurement should be recorded as 
a continuous variable. 
b. Induration/swelling should be evaluated and graded using the functional scale as well as the actual measurement. 
Source: ( FDA 2007) . 
9.9. Adverse Events  
Information on AEs (event term, start and stop date s, severity, relationship to blinded study drug) 
will be collected from the time of signing the informed consent form (ICF) until the final study 
visit after the dose of study drug. See Section  11 for additional information. 
9.10. Prior and Concomitant Medications and Concomitant Procedures 
Prior and concomitant medica tion usage will be recorded from 28 days prior to CD388 
Injection/placebo administration until the final study visit. See Section  8.5 for permitted 
concomitant medications. 
Concomitant procedures to tr eat an AE will be recorded from the time of CD388 Injection/
placebo administration until the final study visit. 
Cidara Therapeutics, Inc.  Protocol CD388.SQ.1.03 
CD388 Injection 
Amendment 1 Confidential  Page 43 of 74 10. ASSESSMENT OF EFFICACY 
Not applicable; this study has no efficacy endpoints. 
Cidara Therapeutics, Inc.  Protocol CD388.SQ.1.03 
CD388 Injection 
Amendment 1 Confidential  Page 44 of 74 11. ASSESSMENT OF SAFETY 
11.1. Safety Parameters 
Safety and tolerability will be assessed by monitoring AEs (including systemic 
reactogenicity/injection site reactions, hypersensitivity reactions, and AESIs), vital signs, 12-lead 
ECGs, clinical laboratory resu lts (hematology, coagulation, serum chemistry, urinalysis), and 
concomitant medication usage throughout the study. 
11.2. Adverse Events 
Adverse events will be collected for all subj ects from the time of signing the ICF through the 
final study visit. The Investigator will assess all AEs and SAEs and will record the following 
information on the appropriate eCRF page: 
x Date of onset 
x Resolution status, and da te of resolution or stabilization if achieved 
x Seriousness 
x Severity 
x Causal relationship to study drug 
x Action taken with  study medication 
Medically indicated laboratory tests (emergency  or unscheduled tests)  should be conducted 
at the local laboratory. The Investigator shoul d employ best medical judgment in determining 
how to manage AEs and SAEs. Any questions regarding AE or  SAE management should be 
directed to the Medical Monitor. 
The Sponsor is responsible for: 
x Confirming the seriousness assessment of all reported AEs and SAEs 
x Confirming the causal relationship between re ported AEs/SAEs and the investigational 
product 
x Assessment of SAEs for expectedness 
The Sponsor will continuously assess the safety of the inves tigational product throughout the 
study. 
11.3. Adverse Event Reporting 
11.3.1. Notification of Serious Adverse Events 
The Sponsor has requirements for expedited reporting of SAEs meeting specific criteria to 
worldwide regulatory authorities in accordance with ICH guidelines and local regulatory 
requirements. Therefore, the Investigator mu st notify the Sponsor immediately regarding any 
SAE that occurs after informed consent via tr ansmission of a Serious Adverse Event Report 
(SAER) by the study site to the safety vendor by email within 24 hours of awareness that an SAE 
Cidara Therapeutics, Inc.  Protocol CD388.SQ.1.03 
CD388 Injection 
Amendment 1 Confidential  Page 45 of 74 has occurred, with a copy to the Medical Monitor. Contact details will be provided to the site(s). 
An optional initial report can be made via telephone, but a completed SAER must still be 
emailed within 24 hours of the siteâ€™s knowledge of the event.  
The Investigational site will be provided with SAER forms wherein the following information 
is requested: 
x Subject identification, Investig ator name, and site number 
x SAE information: event term, onset da te, severity, and causal relationship 
x The outcomes attributable to the event (e .g., death, a life-threatening AE, inpatient 
hospitalization, prolongation of existing hosp italization, a persiste nt or significant 
disability or incapacity, or other important medical event[s]; refer to Section  11.4.4) 
x A summary of relevant test results, pertinent laboratory da ta, and any other relevant 
medical history 
x The date of study drug administration (NOTE: as this is a double-blind study, SAERs should not indicate specific study drug assignments) 
Supplemental information may be requested, including the following: hospital records, 
laboratory results, radiology re ports, progress notes, admission and emergency room notes, 
holding and observation notes, discharge summaries , autopsy reports, and death certificates. 
Relevant eCRF pages can be appended to communicate information relevant to the SAE, 
including study drug administration details, medical history, conco mitant medications, relevant 
laboratory test results, and subj ect outcome information. The SA ER should be emailed within 
24 hours with as much of the above informati on as available at the time. The following minimum 
information is required for reporting an SAE: subject identification, Investigator contact 
information, an AE with a serious outcome, and the Investigatorâ€™s assessment of causal relationship to study drug. Serious adverse events are to be reported immediately and under no 
circumstance should this reporting time exc eed 24 hours following knowledge of the SAE. 
Supplemental information may be  transmitted using a follow-up report and should not delay the 
initial report. The Sponsor may c ontact the investigational site to solicit additional information 
or follow up on the event. 
The Investigator must take all therapeutic m easures necessary for resolution of the SAE. 
Any medications or procedures necessary for treatment of the SAE must be recorded on the 
appropriate pages of the subjectâ€™s eCRF. 
If the Investigator becomes aware of any SAEs th at occur after the study period that are believed 
to be causally related to use of the investig ational product, they should notify the Sponsor 
immediately. The Sponsor will report all suspected unexpected se rious adverse reactions (SUSARs) within the 
required regulatory timeframes to all applicable regulatory authorities and to Investigators as 
required. 
All SAEs that do not meet expedited reporting requirements will be summarized in the 
Development Safety Update Repor t (DSUR) and reporte d annually by the Sponsor as required. 
Cidara Therapeutics, Inc.  Protocol CD388.SQ.1.03 
CD388 Injection 
Amendment 1 Confidential  Page 46 of 74 11.3.2. Notification of Emerging Safety Issues 
Additionally, the Investigator should alert th e Sponsor immediately (under no circumstance 
should this reporting time exceed 24 hours) by contacting the Medical Monitor of any new 
findings that necessitate the impleme ntation of urgent safety measur es to protect subjects against 
any immediate hazard. If time per mits, the Investigator should cont act the Sponsor to discuss the 
hazard and any actions taken or to be taken prior to implementation.  
The Sponsor is responsible for informing other investigators who may need to implement the 
same procedures and for alerting the Competent Authorities and Ethics Committees of the new 
findings and measures taken in accordance with local regulations within  the required timeframes. 
11.4. Definitions 
11.4.1. Adverse Event 
An AE means any untoward medical occurrence associated with the use of a drug or study 
procedure in humans, whether or not considered  drug-related. An AE can be any unfavorable 
and unintended sign (e.g., a c linically significant abnormal laboratory finding), symptom, 
or disease temporally associated with the use of a drug and does not imply any judgment about causality. An AE can arise with any use of the dr ug (e.g., off-label use, use in combination with 
another drug) and with any rout e of administration, formulation, or dose, including an overdose. 
Laboratory abnormalities should not be recorded as AEs or SAEs unless they are associated with 
clinical signs or symptoms, or require me dical intervention. However, each laboratory 
abnormality (e.g., clinically significant changes detected on hematology, coagulation, chemistry, urinalysis) independent from a ny underlying medical condition that requires medical or surgical 
intervention, or that leads to interruption of study drug or discontinuation, must be recorded 
as an AE, or SAE if applicable. If the laborat ory abnormality is part of a clinical condition 
or syndrome, it should be recorded as the syndro me or diagnosis rather than as the individual 
laboratory abnormality. In addition, laboratory abnormalities or other abnormal test assessments (e.g., ECGs) that are associated with signs or sympto ms must be recorded as AEs or SAEs if they 
meet the definition of an AE or SAE as described in this section and in Section  11.4.4, 
respectively. 
11.4.2. Suspected Adverse Reaction 
A suspected adverse reaction is any AE for which there is a reasonable possibility that the drug 
caused the AE. For the purposes of Inves tigational New Drug (I ND) safety reporting, 
â€œreasonable possibilityâ€ means there is evidence  to suggest a causal relationship between the 
drug and the AE. â€œSuspected adverse reactionâ€  implies a lesser degree of certainty about 
causality than â€œadverse reactionâ€, which means any AE caused by a drug.  
11.4.3. Life-Threatening AE or Life-Threatening Suspected Adverse Reaction 
An AE or suspected adverse reaction is considered  â€œlife threateningâ€ if, in the view of either 
the Investigator or Sponsor, its occurrence places the subject at immediate risk of death. It does 
not include an AE or suspected adverse reaction that, had it occurred in a more severe form, 
might have caused death. 
Cidara Therapeutics, Inc.  Protocol CD388.SQ.1.03 
CD388 Injection 
Amendment 1 Confidential  Page 47 of 74 11.4.4. Serious Adverse Event or Serious Suspected Adverse Reaction 
An AE or suspected adverse reaction is consid ered â€œseriousâ€ if, in the view of either 
the Investigator or Sponsor, it results in any of the following outcomes: 
x Death 
x A life-threatening AE â€“ see definition above 
x Inpatient hospitalization or prol ongation of existing hospitalization 
x A persistent or significant incapacity or s ubstantial disruption of the ability to conduct 
normal life functions 
x A congenital anomaly/birth defect in the of fspring of a subject who received study drug 
x Is a suspected transmission of any in fectious agent via a medicinal product  
x Important medical events that may not result in death, be life-threatening, or require 
hospitalization may be considered seri ous when, based upon appropriate medical 
judgment, they may jeopardize the patient or subject and may require medical or surgical intervention to prevent one of the outcomes listed in this definition 
11.4.5. Unexpected AE or Unexpected Suspected Adverse Reaction 
An AE or suspected adverse reac tion is considered â€œunexpectedâ€: 
x If it is not listed in the Investigatorâ€™s Brochur e or is not listed at the nature, severity, 
frequency, or outcome that has been observed 
For example, under this definition, hepatic necrosis would be unexpected (by virtue of greater severity) if the Investigatorâ€™s Brochure referred only to elevated hepatic enzymes or hepatitis. Similarly, cerebral thromboembolism and cerebral vasculitis would be unexpected (by virtue of greater specificity) if the Investigatorâ€™s Broc hure listed only cerebral vascular accidents. 
â€œUnexpectedâ€, as used in this definition, also re fers to AEs or suspected adverse reactions that 
are mentioned in the Investigatorâ€™s Brochure as occurring with a class of drugs or as anticipated 
from the pharmacological properties of the drug but are not specifically mentioned as occurring 
with the particular dr ug under investigation. 
11.4.6. Adverse Events of Special Interest 
Adverse events of special interest (AESIs) include anaphylaxis (refer to Appendix 3  for 
diagnostic criteria and management). 
11.4.7. Emerging Safety Issue 
Any new safety information that may lead to a reassessment of the risk/benefit balance of the 
investigational product a nd/or impact subjectsâ€™ he alth. Examples include: 
x Any new safety issue relating to the conduct of  the clinical trial that may impact the 
safety of the trial subjects such as significant safety results from a recently completed non-clinical study or early termination or temporary suspension of a trial for safety reasons that is conducted on the same investigational product 
Cidara Therapeutics, Inc.  Protocol CD388.SQ.1.03 
CD388 Injection 
Amendment 1 Confidential  Page 48 of 74 x Recommendations from a Data Review Committee that may affect the safety of trial 
subjects  
11.4.8. Urgent Safety Measure 
An urgent safety measure (USM) is a procedure not defined by the protocol that can be put in place immediately, without prior authorizati on from Ethics Committees or Regulatory 
Authorities, to protect study subjects from any im mediate hazard to their health and safety. 
11.5. Adverse Event Classification 
11.5.1. Relationship to Study Drug 
The Investigatorâ€™s assessment of causality must be provided for all AEs (serious and nonserious; 
Table 6 ). An Investigatorâ€™s causality assessment is the determination of whether there exists 
a reasonable possibility that the study dr ug caused or contributed to an AE. 
These criteria, in addition to good clinical judgmen t, should be used as a guide for determining 
the causal assessment. If the event is thought to be unrelated to study drug administration, 
an alternative explana tion should be provided. 
Table 6: Table Guidelines for Assessing Relationship of Event to Study Drug 
Unrelated There is little or no chance that  the study drug caused the adverse event (AE); other conditions, 
including concurrent illnesses, progression or e xpression of the disease state, or a reaction 
to a concomitant medication best explain the event. 
Related The association of the AE with the study drug is unknown; however, the AE is not clearly due to 
another condition, or a reasonable temporal as sociation exists between the AE and study drug 
administration and, based on the Investigator's clinical experience, the association of the AE with the study drug seems likely. 
11.5.2. Severity 
For injection site reactions, the Investigator will use the grading scale in Table 5 . To describe the 
intensity of all other AEs following general categorical descriptors outlined in the DAIDS table 
for Grading the Severity of Adu lt and Pediatric Adverse Events ( DAIDS 2017), the grading scale 
in Table 7  will be used. 
Table 7: Guidelines for Severity Assessments 
Grade 1  
Mild Mild symptoms causing no or minimal interference with usual social and functional activities 
with intervention not indicated  
Grade 2  
Moderate  Moderate symptoms causing greater than minimal interference with usual social and functional activities with intervention indicated
 
Grade 3  
Severe  Severe symptoms causing inability to perform usual social and functional activities with intervention or hospitalization indicated
 
Grade 4  
Potentially Life 
Threatening Potentially life-threatening symptoms causing inability to perform basic self-care functions 
with intervention indicated to prevent permanent impairment, persistent disability, or death 
Grade 5  
Death Fatal 
Refer to the DAIDS table for Grading the Severity of Adult and Pediatric Adverse Events  for details regarding event grading. 
Cidara Therapeutics, Inc.  Protocol CD388.SQ.1.03 
CD388 Injection 
Amendment 1 Confidential  Page 49 of 74 11.5.3. Serious Adverse Event 
Any adverse experience occurring at any dose of study medication that occurs from the time 
of informed consent through the final study visit, are considered serious if they result in any of 
the outcomes listed in Section  11.4.4. 
Hospitalization for a planned or elective procedur e or surgery for a pre-existing condition that 
has not worsened is not considered an SAE. 
11.6. Adverse Event Follow Up 
All unresolved SAEs and study drug-related AEs will be fo llowed by the study staff until 
resolution or deemed stable , regardless of severity. 
11.7. Adverse Event Management 
The Investigator should employ best medical j udgement in determining how to manage AEs. 
Any questions regarding AE management should be directed to the Medical Monitor. 
11.8. Risks for Women of Childbearing Potential or During Pregnancy 
The risks of CD388 Injection in pregnant or  lactating/nursing women are unknown. Pregnant 
or nursing female subjects are excluded from this study. 
Subjects must be instructed to inform the Investigator immediately if they or their partner 
becomes pregnant during the study. In the case of a partner pregnancy, partner informed consent must be obtained prior to collecting info rmation related to the pregnancy and to allow 
the Investigator to follow them for the outcome of the pregnancy. In th e event of a confirmed 
pregnancy, the following ac tions should be taken: 
x The pregnancy should be reported to the Sponsor within 24 hours of the subject notifying the Investigator using the applicable Pregnancy Report Form. 
x The Investigator should counsel female subj ects regarding the possible effects of CD388 
Injection exposure on the fetus and the need to inform the study site of the outcome of the 
pregnancy. 
x The subject or subjectâ€™s partner, if consented, should be monitored until the postnatal day 28 or until termination of  the pregnancy. The outcome should be reported using 
the Pregnancy Outcome or Abnor mal Pregnancy Outcome form. 
Pregnancy is not an AE, in and of itself. Ho wever, any pregnancy complication or elective 
termination of a pregnancy for medical reasons will be recorded as an AE or SAE. A spontaneous abortion is always considered an SA E and will be reported as described in the AE 
and SAE sections. Furthermore, any SAE occurring as an adverse pregnancy outcome post-study must be reported to the Medical Monitor. 
Cidara Therapeutics, Inc.  Protocol CD388.SQ.1.03 
CD388 Injection 
Amendment 1 Confidential  Page 50 of 74 12. STATISTICAL METHODS 
A Statistical Analysis Plan (SAP) will be prepared and finalized before unblinding for the first 
interim analysis. Any deviations from the final SAP will be described an d justified in the study 
report. All statistical analyses will be performed using SASÂ®. 
Descriptive statistics, including the numbers and percentages for categorical variables, and the 
numbers, means, standard deviations, medi ans, minimums, and maximums for continuous 
variables, will be provided. All data will be summarized separa tely by dose level and study drug 
(CD388 Injection or placebo). Listings of i ndividual subject data will also be produced. 
Safety, tolerability, and PK will be summarized using descriptive statistics. There will be no 
formal hypothesis testing.  
12.1. Analysis Populations 
Analysis populations are: 
x Safety Population: all subjects w ho receive any amount of study drug 
x PK Analysis Population: all subjects w ho receive CD388 Injecti on and who have any 
blood samples analyzed 
12.2. Analysis of Study Population and Subject Characteristics 
Demographics (including age, race, ethnicity, and gender), ba seline assessments (including 
height, weight, and BMI), medi cal history, and administration of study drug will be summarized 
for the Safety Population. 
12.3. Safety Analyses 
Safety will be evaluated by presenting summaries of AEs and SAEs, ECGs, clinical laboratory evaluations (hematology, coagul ation, serum chemistry, urinalys is), and vital signs. Adverse 
events will be coded using the Medical Dictionary for Regulatory Activities (MedDRA). The incidence of TEAEs and AESIs will be presented by System Organ Class (SOC) and Preferred Term (PT), relatio nship to study drug, and severity. A TEAE is defined as an AE 
that emerges during or after study drug administr ation having been absent pre-treatment, or 
worsens relative to the pre-treatment state, a nd through the final study visit. In addition, the 
incidence of serious TEAEs and TEAEs leadi ng to discontinuation of study drug or from the 
study will be presented by SOC and PT.  
Descriptive statistics for clinical laboratory test results, ECG parameters, and vital signs, and for 
changes from Baseline, will be presented by time point. The incidences of potentially clinically 
significant (PCS) clinical laboratory results, ECG parameters, and vital signs will also be 
summarized by time point.  
A summary of the injection site evaluation will be presented. The number and percentage of 
subjects with any local reaction will be provided, as will the number and percentage of subjects 
with pain, tenderness, erythema /redness, and induration/swelling. The severity of each local 
reaction will also be presented. 
Cidara Therapeutics, Inc.  Protocol CD388.SQ.1.03 
CD388 Injection 
Amendment 1 Confidential  Page 51 of 74 12.4. Pharmacokinetic Analyses 
Based on the individual plasma concentration-time data, using the actual sampling times 
(see Schedule of Events, Table 1 ), the following PK parameters will be included:  
x maximum plasma concentration (C max) 
x time to maximum plasma concentration (T max) 
x terminal elimination half-life (t Â½) 
x apparent clearance (CL/F) 
x apparent volume of distribution (V Z/F)  
x area under the plasma concentration-time curve from time 0 to time of last quantifiable sample (AUC
0-last) 
x area under the plasma concentration-time curve from time 0 extrapolated to infinity (AUC
0-Â’) 
CD388 concentration in the upper respirat ory tract will also be determined.  
Pharmacokinetic parameter estimation will be performed by non-compartmental analysis (NCA) with Phoenix
Â® WinNonlinÂ® version 8 or higher. The actual elapsed sampling times relative to 
dosing will be recorded during the study and will be  used in the NCA analysis. Pharmacokinetic 
data handling and analysis will be further detailed in the SAP. 
Descriptive statistics will be cal culated for plasma concentrati ons at each individual time point 
and for all PK parameters. Mean and individual plasma concentration-time profiles will be 
presented graphically. Inferen tial statistics will also be c onducted for log transformed PK 
exposure parameters versus historical c ontrol data in Western subjects from Study 
CD388.IM.SQ.1.01. 
Pharmacokinetic samples for CD 388 from this study may also be included in a population PK 
analysis, which will be reported separately. 
12.5. Analyses of Pharmacogenomics, Exploratory Biomarkers, 
and Anti-Drug Antibodies 
Analysis of the ADA results is to be determined  and may include determin ation of the subjectâ€™s 
positive/negative ADA status at baseline, treatment -emergent ADA in subjects with a negative 
baseline, as well as a post-baseline increase in titer for subjects with positive ADA at baseline. 
Pharmacogenomics, and exploratory biomarkers will be reported separately. 
12.6. Analyses of Respiratory Tract Infections 
The number and percentage of subjects with any RTI will be provided. 
12.7. Interim Analysis 
After 50% of Cohort 1 subjects have complete d study drug administration and have undergone 
protocol-specified procedures and DVVHVVPHQWVIRUÂ•  days, the Principal Investigator (PI) 
Cidara Therapeutics, Inc.  Protocol CD388.SQ.1.03 
CD388 Injection 
Amendment 1 Confidential  Page 52 of 74 and Sponsor will review blinded safety data: AEs (including syst emic reactogeni city/injection 
site reactions, hypersensitivity reactions, and AE SIs), vital signs, 12-lead ECGs, and clinical 
laboratory results (hematology, coagulation, serum ch emistry, urinalysis) to determine the safety 
and tolerability of the study drug. The incidence and severity of AEs, and any adverse changes in 
vital signs, clinical laboratory findings, and ECGs will be considered when determining safety 
and tolerability of study drug. If the GRVHLVGHWHUPLQHGWREHVDIHDQGZHOOWROHUDWHGÂ•GD\V
after dosing, Cohort 2 will be enrolled. Enrollme nt of the remaining 50% of Cohort 1 will 
continue while the safety data of the first 50% of Cohort 1 is being reviewed. Similar processes 
will be followed for dose escalation from Cohort 2 to Cohort 3. 
After the final subject of Cohort 2 has comple ted the Day 90 visit, C ohorts 1 and 2 may be 
unblinded for a formal interim data analysis. In addition, unblinded data reviews may occur as 
needed. 
12.8. Determination of Study Sample Size 
A total of 27 subjects will be enrolled in this study, with 21 of these subjects to receive CD388 
Injection and 6 to receive placebo. The number of  subjects was selected to allow sufficient 
evaluation of safety and tolerability, and PK, and is consistent with standards of practice for Phase 1 ethnic bridging studies. 
12.9. Handling of Dropouts and Missing, Unused, and Spurious Data 
Every effort will be made to collect all data at specified times. Handling of missing data will be detailed in the SAP. 
12.10.  Subject Disposition 
Enrollment and discontinuations from the study will be summarized, including the reasons for 
discontinuation. 
12.11.  Deviation Reporting 
Protocol deviations will be summarized. Protocol deviations are defined as any variation from 
the protocol, including enrollment of a subject who did not meet all inclusion and exclusion 
criteria and failure to perform the assessments and procedures within the required time frame. 
Cidara Therapeutics, Inc.  Protocol CD388.SQ.1.03 
CD388 Injection 
Amendment 1 Confidential  Page 53 of 74 13. INVESTIGATOR REQUIREMENTS 
13.1. Protocol Adherence 
The Investigator must adhere to the protocol as detailed in this document and agree that the 
Sponsor must approve any change to the protoc ol before seeking approval from the IRB/IEC. 
The Investigator will be responsible for enro lling only those subjects who have met the study 
selection criteria. 
13.2. Electronic Case Report Forms 
The contract research organization will make the eCRF accessible to authorized personnel 
over the internet from an electronic data capture (EDC) system used for the recording of study 
data as specified by this protocol. All eCRFs must be comp leted by trained study personnel. 
The Investigator is responsible for ensuring th at the eCRF data are entered and completed 
in a timely manner. 
Once all data queries and issues have been resolved for each subject, the Investigator will 
electronically sign each subjectâ€™s eCRF to attest to the accuracy of the data. 
13.3. Source Document Maintenance 
Source documents are defined as documentation related to original observations and activities 
of a clinical investigation. Source documents  may include, but are not limited to, study progress 
notes, study- or subject-specifi c e-mail correspondence, computer  printouts, laboratory data, 
and recorded data from automated instruments. All source documents produced in this study will 
be maintained by the Investigat or and made available for in spections by the Sponsor and by 
regulatory authorities. The original signed ICF for each participating subject  shall be filed with 
records kept by the Investigator, and a copy shall be given to the subject. 
13.4. Study Monitoring  Requirements 
An authorized Sponsor representative will conduct site visits to inspect study data, subjectsâ€™ 
medical records, and eCRFs in accordance with ICH guidelines, GCP, and the foreign 
regulations and guidelines, as applicable. A monitor will be utilized for monitoring ongoing drug accountability and adherence to protocol procedures. 
The Investigator will allow representatives of the Sponsor and regulatory authorities to inspect 
facilities and records relevant to this study. 
13.5. Study Completion 
The Sponsor requires the following data and materials before a study can be considered complete 
or terminated: 
x Laboratory findings, clinical data, and all special test resu lts from screening throughout 
the study  
x eCRFs (including data querie s) properly completed by appropriate study personnel, 
signed and dated by the Investigator 
Cidara Therapeutics, Inc.  Protocol CD388.SQ.1.03 
CD388 Injection 
Amendment 1 Confidential  Page 54 of 74 x Copies of complete drug accountability record s (drug inventory log and an inventory 
of returned or destro yed clinical material) 
x Copies of protocol amendments and IRB/IEC approval and notification, if appropriate 
x A summary of the study prepared by the In vestigator (an IRB/IEC summary letter 
is acceptable) 
End of Study Conduct, for the purpose of clinical trial registries, end of trial notifications to 
regulatory authorities and IRBs/ECs, will be the latest date on which the last visit in time of any 
study subject occurs. 
Cidara Therapeutics, Inc.  Protocol CD388.SQ.1.03 
CD388 Injection 
Amendment 1 Confidential  Page 55 of 74 14. QUALITY CONTROL AND QUALITY ASSURANCE  
Written Standard Operating Proce dures (SOPs) will be followed to ensure that the study is 
conducted, and data are generated, documented (recorded), and reported in compliance with the 
protocol, GCP, and the applicable regulatory requirements. Quality control will be applied to 
each stage of data handling. Regular monitori ng, as defined in ICH GCP E6(R2), Section 1.38, 
â€œThe act of overseeing the progress of a clinical  trial, and of ensuring that it is conducted, 
recorded, and reported in accordance with the protocol, SOPs, GCP, and the applicable regulatory requirement(s)â€, will be c onducted throughout the conduct of the study. 
As defined in ICH GCP E6(R2), Section 5.18.1, the purpose of monitoring is to verify that: 
x Rights and well-being of the human subjects are protected. 
x The reported study data are accurate, complete , and verifiable from source documents. 
x The conduct of the study is complia nt with the currently approved 
protocol/amendment(s), with GCP, and with the applicable regulatory requirements. 
x Monitoring is an integral role in the quality control of a clinical trial and is designed to verify the quality of the study. 
To fulfill the Quality Assurance requirements of  GCP, audits will be  conducted to assess 
and assure the reliab ility and integrity of a studyâ€™s quality control systems and recognized 
standards. 
As defined in ICH GCP E6(R2), Secti on 5.19, the purposes of an audit are to: 
x Ensure subject safety 
x Assure compliance to study protocol proced ures, regulatory requirements, and SOPs 
x Assure data quality 
Cidara Therapeutics, Inc.  Protocol CD388.SQ.1.03 
CD388 Injection 
Amendment 1 Confidential  Page 56 of 74 15. PROTECTION OF HUMAN SUBJECTS 
This study will be conducted in compliance with the ICH Technical Requirements for 
Registration of Pharmaceuticals for Human Use E6(R2) Guideline for Good Clinical Practice, 
the ethical principles of the Declaration of Helsinki, FDA GCP guidelines, and any additional 
national or IRB/IEC-re quired procedures. 
15.1. Informed Consent 
This study will be conducted in compliance with ICH E6(R2) Guideline for Good Clinical 
Practice pertaining to informed consent. Subjects will give written consent to participate in the study at the first visit, prior to initiation of any study-related procedures, after having been 
informed about the nature and purpose of the study, participation and termination conditions, 
risks, and benefits. If a subject is unable to provide written informed consent, the subjectâ€™s legally acceptable representative (i.e., acceptable  to ICH and local law, as applicable) may 
provide written consent, as approved according to institution-specific guidelines. The ICF must 
be signed and dated by the subject, or the subjectâ€™ s legally acceptable representative, prior to 
study participation. A copy of the ICF must be pr ovided to the subject or the subjectâ€™s legally 
acceptable representative. If applicable, it will be provided in certified translation for non-English-speaking subjects. Signed ICFs must remain in the subjectâ€™s study file and be 
available for verification by Sponsor at any time. 
15.2. IRB/IEC Approval 
This protocol, the ICF, and all relevant supporting data must be submitted to the IRB/IEC 
for approval. The protocol, ICF, and any adve rtisement used to recruit study subjects must 
be approved by the IRB/IEC. Approval by the IRB/IEC of the prot ocol and ICF must be obtained 
before the study may be initiated. 
The Investigator is responsible for informing th e IRB/IEC of any changes made to the protocol, 
and to advise them, at least once a year, about the progress of the study. The Investigator is also 
responsible for notifying the IRB/IEC of any significant AEs that occur during the study. 
Cidara Therapeutics, Inc.  Protocol CD388.SQ.1.03 
CD388 Injection 
Amendment 1 Confidential  Page 57 of 74 16. DATA HANDLING AND RECORD KEEPING 
Training sessions, regular monitoring of Inve stigators by Sponsor-designated personnel, 
instruction manuals, data verifica tion, crosschecking, and data audits  will be performed to ensure 
quality of all study data. Investig ator meetings may be perform ed to prepare Investigators 
and other study personnel for appr opriate collection of study data. 
The Sponsor will review and validate study da ta as defined in the monitoring plan. 
It will be the responsibility of the Investigator to ensure that the essential documents 
are available at the study site. Any or all thes e documents may be subject to, and should be 
available for, monitoring by the Sponsor or in spection by the regulatory authorities as defined 
in the monitoring plan. 
16.1. Direct Access to Source Data/Documentation 
The Investigator agrees by his/ her participation that the results of this study may be used for 
submission to national or international registration. If required, these authorities will be provided 
with the name of the Investigator and his or  her address, qualifica tions, and extent of 
involvement. It is understood that the Investigator  is required to provide  Sponsor with all study 
data, complete reports, and access to all study records. 
Data generated by this study mu st be available for inspecti on by any regulatory authorities, 
by the Sponsor and by the IRB/IEC as appropriate . At a subjectâ€™s request, medical information 
may be given to his or her pe rsonal physician or other appropri ate medical personnel responsible 
for his or her welfare. Medical information obtained from subjects during the course of this study 
is confidential and disc losure to third parties other than those noted above is prohibited. 
16.2. Study Drug Accountability 
All supplies of CD388 Injection/ placebo required for completion of  this study will be provided 
by the Sponsor. It is the responsibility of the unbl inded Pharmacy or study staff to ensure that 
a current record of drug inventory and drug accountability is mainta ined. Inventory and 
accountability records must be readily available for inspection by the monitor and are open to 
inspection at any time by applicable regulatory authorities. 
16.3. Retention of Records 
Essential documents should be retained until at least 2 year s after the last approval of 
a marketing application in an ICH region and until there are no pending or contemplated 
marketing applications in an ICH region or at  least 2 years have elapsed since the formal 
discontinuation of clinical deve lopment of the investigational product and shipme nt and delivery 
of the drug for investigational use is discontinued. These documents should be retained for a longer period, however, if required by the ap plicable regulatory requirements of specific 
ICH and non-ICH countries, or by an agreement with the Sponsor. The Sponsor will inform 
the Investigator/institution as to when thes e documents no longer need to be retained. 
Cidara Therapeutics, Inc.  Protocol CD388.SQ.1.03 
CD388 Injection 
Amendment 1 Confidential  Page 58 of 74 16.4. Long-term Retention of Samples for Additional Future Research 
Samples collected in this study may be stored  for up to 15 years (or according to local 
regulations) for additional research. Samples will only be used for research related to influenza 
virus infection, flu-like disease, and safety, reactogenicity, and immunogenicity of CD388. They 
may also be used to develop tests/assays related to CD388 and influenza. The research may 
begin at any time during the study or the post-study storage period. 
Stored samples will be coded throughout the sample storage a nd analysis process and will not be 
labeled with personal identifiers. Subjects may withdraw their consent for their samples to be stored for research.  
Cidara Therapeutics, Inc.  Protocol CD388.SQ.1.03 
CD388 Injection 
Amendment 1 Confidential  Page 59 of 74 17. FINANCING AND INSURANCE 
The financing and insurance for this study are outlined in the Clinical Trial Agreement. 
Cidara Therapeutics, Inc.  Protocol CD388.SQ.1.03 
CD388 Injection 
Amendment 1 Confidential  Page 60 of 74 18. PUBLICATION POLICY 
The data generated in this clinical study are the exclusive property of the Sponsor and are 
confidential. Authorship on any publication of  the results from this study will be based 
on contributions to study design, enrollment, data  analysis, and interpretation of results. 
Cidara Therapeutics, Inc.  Protocol CD388.SQ.1.03 
CD388 Injection 
Amendment 1 Confidential  Page 61 of 74 19. REFERENCES 
Abbasi J. The search for a universal flu vaccine heats up. JAMA . 2019; 322(20): 1942â€“1944. 
Brammer L. Influenza Surveillance Update. Pr esented to ACIP June 27, 2019. Available at: 
https://stacks.cdc.gov/view/cdc/80753. Accessed 20 July 2022. 
FDA Guidance for Industry: Estimating the Maximu m Safe Starting Dose in Initial Clinical 
Trials for Therapeutics in Adult Hea lthy Volunteers. July 2005. Available at: 
https://www.fda.gov/media/72309/dow nload. Accessed 20 July 2022. 
FDA Guidance for Industry: Toxicity Gradi ng Scale for Healthy Adult and Adolescent 
Volunteers Enrolled in Preventive Vaccine Clinical Trials. September 2007. Available at: 
https://www.fda.gov/media/73679/dow nload. Accessed 20 July 2022. 
Flannery B, Chung J, Ferdinands J, Smith E,  Campbell A, Ogokeh C. Preliminary estimates of 
the 2018-2019 seasonal influenza vaccine effectiv eness against medically attended influenza 
from three U.S. networks. Presented to ACIP June 27, 2019. Available at: 
https://stacks.cdc.gov/view/cdc/80754. Accessed 20 July 2022. 
Iuliano AD, Roguski KM, Chang HH, Muscatello DJ, Palekar R, Tempia  S, et al. Global 
Seasonal Influenza-associated Mortality Collaborator Network. Estimates of global seasonal 
influenza-associated respirat ory mortality: a modelling study. Lancet . 2018; 391(10127): 
1285â€“  1300. 
National Institute of Allergy and Infectious Diseases. Division of AIDS (DAIDS) Table for 
Grading the Severity of Adult and Pediat ric Adverse Events, corrected v2.1. July 2017. 
Available at: https://rsc.niai d.nih.gov/sites/default/f iles/daidsgradingcor rectedv21.pdf. Accessed 
20 July 2022. 
Okoli GN, Otete HE, Beck CR, Nguyen-Van-Tam JS . Use of neuraminidase inhibitors for rapid 
comtainment of influenza: a sy stematic review and meta-analy sis of individual and household 
transmission studies. PLoS One . 2014; 9(12): e113633. 
Paules C, Subbarao K. Influenza. Lancet . 2017; 390(10095): 697â€“708. 
Sampson HA, Munoz-Furlong, Campbell RL, T homas S, Wood JP, Decker WW. Second 
symposium on the definition and management of anaphyl axis: Summary reportâ€”Second 
National Institute of A llergy and Infectious Disease/Food Allergy and Anaphylaxis Network 
symposium. J Allergy Clin Immun . 2006; 117(2): 391â€“397. 
Cidara Therapeutics, Inc.  Protocol CD388.SQ.1.03 
CD388 Injection 
Amendment 1 Confidential  Page 62 of 74 20. APPENDICES 
 
Cidara Therapeutics, Inc.  Protocol CD388.SQ.1.03 
CD388 Injection 
Amendment 1 Confidential  Page 63 of 74 APPENDIX 1.  ACCEPTABLE METHODS OF CONTRACEPTION 
An acceptable method of contracep tion includes one of the following: 
x Abstinence from heterosexual intercourse 
x Hormonal contraceptives (birth control pills, injectable/implant/insertable hormonal birth 
control products, tr ansdermal patch) 
x Intrauterine device (with or without hormones) 
x A double barrier method (e.g., condom and spermicide) 
 
Cidara Therapeutics, Inc.  Protocol CD388.SQ.1.03 
CD388 Injection 
Amendment 1 Confidential  Page 64 of 74 APPENDIX 2.  ECG AND VITAL SIGN ABNORMALITIES 
 
Important abnormalities from the ECG readings are summarized below:  
Abnormality  ECG Parameter  
HR PR QRS  QTcF  
Abnormalities on actual values  
Abnormally low <45 bpm NA - - 
Abnormally high Â•ESP  >220 msec Â•PVHF  - 
Borderline prolonged QT (males) - - - 450 msec to Â”PVHF  
Borderline prolonged QT (females)       470 msec to Â”PVHF  
Prolonged QT - - - 481 msec to Â”500 msec 
Pathologically prolonged QT - - - >500 msec 
Abnormalities on changes from baseline  
Normal QTcF change - - - <30 msec 
Borderline QTcF change - - - 30 msec WRÂ”60 msec 
Abnormally high QTcF change - - - >60 msec 
Abbreviations: bpm = beats per minute; HR = heart rate; NA = not applicable; PR = PR interval; QRS = QRS interval; 
QTcF = QT interval corrected for heart rate using Fridericiaâ€™s formula. 
 
Important abnormalities for vital signs are summarized below: 
Abnormality  Vital Signs Parameter  
HR DBP SBP 
Abnormally low  Â”ESP  Â”PP+J  Â”PP+J  
Grade 1 or mild  - >90 mmHg to <100 mmHg  >140 mmHg to <160 mmHg  
Grade 2 or moderate  - Â•PP+JWRPP+J  Â•PP+JWRPP+J  
Grade 3 or severe  - Â•PP+J  Â•PP+J  
Abnormally high  Â•ESP  - - 
Abbreviations: DBP = diastolic blood pressure; HR = heart rate; SBP = systolic blood pressure. 
  
 Grade 1 Grade 2 Grade 3 Grade 4 
Fever a 38.0 to <38.6Â°C 
(100.4 to <101.5Â°F) Â•WRÂƒ&  
(Â•WRÂƒ) ) Â•WRÂƒ&  
Â•WRÂƒ)  Â•Âƒ&  
Â•Âƒ)  
a. Non-axillary temperatures only. 
 
For tachypnea and hypoxia, refer to the grading scale in Table 7 . 
Cidara Therapeutics, Inc.  Protocol CD388.SQ.1.03 
CD388 Injection 
Amendment 1 Confidential  Page 65 of 74 APPENDIX 3.  DIAGNOSTIC CRITERIA AND MANAGEMENT FOR 
ANAPHYLAXIS 
Diagnostic Criteria  for Anaphylaxis 
Anaphylaxis is highly likely when any one of the following 3 criteria are fulfilled: 
1. Acute onset of an illness (minutes to seve ral hours) with involvement of the skin, 
mucosal tissue, or both (e.g., generalized  hives, pruritus or flushing, swollen 
lips, -tongue, -uvula) 
and at least one  of the following: 
a. Respiratory compromise (e.g., dyspnea, whee ze-bronchospasm, stridor, reduced peak 
expiratory flow, hypoxemia) 
b. Reduced blood pressure or associated  symptoms of end-organ dysfunction 
(e.g., hypotonia [collapse], syncope, incontinence) 
2. Two or more of the following that occur rapi dly after exposure to a likely allergen for 
that subject (minutes to several hours): 
a. Involvement of the skin-mucosal tissue (e .g., generalized hives, itch-flush, swollen 
lips-tongue-uvula) 
b. Respiratory compromise (e.g., dyspnea, whee ze-bronchospasm, stridor, reduced peak 
expiratory flow, hypoxemia) 
c. Reduced blood pressure or associated sy mptoms (e.g., hypotonia [collapse], syncope, 
incontinence) 
d. Persistent gastrointestinal symptoms  (e.g., crampy abdominal pain, vomiting) 
3. Reduced blood pressure after e xposure to known allergen for that subject (minutes to 
several hours): a. Systolic blood pressure < 90 mmHg or >30% decrease from that person's baseline 
 
Management of Anaphylaxis 
1. Epinephrine:  When a subject meets any of the di agnostic criteria, the subject should 
receive epinephrine immediately, as it is the tr eatment of choice in anaphylaxis. Aqueous 
epinephrine, 0.01 mg/kg (maximum dose, 0.5 mg) administered intramuscularly every 
5 to 15 minutes as necessary, is the re commended dosage for controlling symptoms 
and maintaining blood pressure. The 5-minute interval between injections can be 
liberalized to permit more frequent injections if deemed necessary by the clinician. 
2. Oxygen and adrenergic agonists:  High-flow oxygen (through a nonrebreather mask 
or endotracheal tube) should be administe red to subjects experiencing respiratory 
symptoms or hypoxemia. Those who are hem odynamically unstable might benefit from 
R[\JHQDVZHOO,QKDOHGÈ•
2-agonists, such as albuterol, mi ght be useful for bronchospasm 
refractory to epinephrine. 
Cidara Therapeutics, Inc.  Protocol CD388.SQ.1.03 
CD388 Injection 
Amendment 1 Confidential  Page 66 of 74 3. Positioning of  the subject: Subjects in anaphylactic shock (i.e., those with anaphylaxis 
and signs of critical organ hypoperfusion) should be placed in a recumbent position with 
the lower extremities elevated unless precluded by shortness of breath or vomiting. 
4. Fluid resuscitation:  Subjects who remain hypotensive despite epinephrine should have 
aggressive fluid resuscitation. La rge volumes of crystalloid might be needed in the first 
5 to 10 minutes; in severe reactions with hypotension, up to 35% of the blood volume might extravasate in the first 10 minutes, and vasodilatation can cause pooling, with even more reduction in the effective bl ood volume and thus distributive shock. 
5. Vasopressors:  Potent vasopressors, such as noradr enaline, vasopressi n, or metaraminol, 
might be required to overcome vasodilatation if epinephrine and fluid resuscitation have 
failed to maintain a systolic blood pressure of greater than 90 mmHg. 
6. H
1- and H 2-antihistamines:  Antihistamines (H 1- and H 2-antagonists) are slower in onset 
of action than epinephrine, have little effect on blood pressure, and should be considered a second-line treatment for anaphylaxis. 
7. Corticosteroids:  Because the onset of action is slow, steroids are not useful in the acute 
management stage. It has been suggested th at their use might prevent a protracted or 
biphasic reaction. 
8. *OXFDJRQIRUSHUVLVWHQWK\SRWHQVLRQLQVXEMHFWVWDNLQJÈ• -blocker: Theoretically, there 
DUHPXOWLSOHPHFKDQLVPVE\ZKLFKÈ• -blockade could blunt the response to epinephrine. 
If administration of epinephrine in these subjects is ineffective, administration of glucagon can be attempted. Glucagon is thought to reverse refractory hypotension 
and EURQFKRVSDVPE\DFWLYDWLQJDGHQ\ODW HF\FODVHLQGHSHQGHQWRIWKH È•-receptor; 
however, the occurrence and importance of this  mechanism of action in anaphylaxis is 
unproved. 
9. Observation: After the treatment of an anaphyl actic reaction, an observation period 
should be considered for all subjects as th e reaction might recur as the effect of 
epinephrine wears off (intramuscular epinephrine results in increased serum levels for an hour or more) and because of the risk of  a biphasic reaction (1â€“72 hours after the acute 
reaction).  
 
Source: Sampson 2006 .
Cidara Therapeutics, Inc.  Protocol CD388.SQ.1.03 
CD388 Injection 
Amendment 1 Confidential  Page 67 of 74 APPENDIX 4.  RASH MANAGEMENT 
For subjects reporting rash, the following should be performed: 
All rashes will be discussed betw een the Investigator and the Sponsor, and in case of a causal 
relationship between the rash and the study dr ug, then the following visits and assessments 
will be performed as indicated below and in the â€œVisit Schedule for Rash Managementâ€ 
(see Appendix 5). Unscheduled follow-up visits for close follow-up of rash will be performed 
based on the grade (severity) of the rash. At th e Investigatorâ€™s discretion, additional visits 
and assessments may be performed. 
The rash event should be captured in the AE sect ion of the electronic case report form (eCRF), as 
well as in more detail in the specific rash assessment pages of the eCRF. 
In case of rash, blood samples need to be collect ed for safety laboratory testing, and processed by 
the local laboratory. These samples need to be collected during the unscheduled visits as 
described below and in Appendix 5. A copy of the local laborator y reports should be anonymized 
and will be retrieved by the monitor. 
The following parameters need to be tested: aspartate aminotransferase (AST), alanine 
aminotransferase (ALT), creatinin e, erythrocyte sedimentation rate, and a complete blood cell 
count (including hemoglobin, hematocrit, red blood cell [RBC] count, white blood cell [WBC] count, neutrophils, lymphocytes, monocytes, eo sinophils, basophils, and platelet count). 
Digital pictures need to be ta ken as described below and in Appendix 5. Digital pictures will be 
anonymized and stored on the Sponsorâ€™s secure se rver. Only the study team will have access to 
the pictures. 
The subject may be treated symptomatically until the rash resolves. If the rash is considered to be 
most likely due to concomitant  illness or non-study medication, standard management, including 
discontinuation of the likely causative agent, shou ld be undertaken, and th e continuation of the 
subject in the study should be discussed with the Sponsor. 
Dermatologist fees for evaluating subjects who experience a rash will be reimbursed by the 
Sponsor. 
The following grades are based on th e DAIDS Toxicity Grading Scale ( DAIDS 2017 ) with 
adaptations made by the Sponsor: Subjects should be informed that they should contact their doctor and visit the clinic 
immediately (unscheduled visit, day 1 of  the rash) when they notice any rash. 
Grade 1 Rash 
A Grade 1 rash is defined as erythema . 
x Subjects may continue the inta ke of study drug(s) (at the Investigatorâ€™s discretion). 
x An unscheduled visit for initial rash evaluation (day 1 of the rash) is required. 
x Assessment of safety blood samples by the lo cal laboratory is required. A copy of the 
local laboratory report should be anonymized  and will be retrieved by the monitor. 
Cidara Therapeutics, Inc.  Protocol CD388.SQ.1.03 
CD388 Injection 
Amendment 1 Confidential  Page 68 of 74 x Digital pictures should be  taken within 24 hours after the onset of the rash. 
x Referral to a dermatologist is only needed if the rash diagnosis is uncertain (preferably 
within 24 hours after the onset of the rash). A copy of the dermatologistâ€™s report should 
be anonymized and will be retrieved by the monitor. 
x Cetirizine, levocetirizine, topical corticosteroids, or antipruritic agents may be prescribed. 
x The description of the rash should be reported per â€˜Unscheduled  Visit in Case of Rashâ€™ in 
the eCRF (i.e., the initial rash assessment pages). 
For close follow-up of the rash, unscheduled visits will also be performed 1 and 7 days after the initial assessment of the rash. At these visits, sa fety blood samples and dig ital pictures should be 
taken. The follow-up rash assessment pages of the eCRF should be completed for all follow-up 
visits. For these and all subsequent local laboratory blood sample assessments: a copy of the 
local laboratory reports should be anonymized  and will be retrie ved by the monitor. 
If the rash is unresolved after 7 days, additiona l unscheduled visits may be performed at the 
Investigatorâ€™s discretion. Upon resolution/stabiliza tion of the rash, digital pictures should be 
taken and the final rash assessment pa ges of the eCRF should be completed. 
The subject should be advised to contact th e Investigator immediat ely if there is any 
worsening of the rash, if  any systemic signs or symptoms appear, or if mu cosal involvement 
develops. 
In case the rash evolves from a Grade 1 to a highe r grade, additional unscheduled visits have to 
be conducted according to the guidelines fo r Grade 2 or Grade 3â€“4 rash, respectively. 
Grade 2 Rash A Grade 2 rash is defined as diffuse, maculopapular rash OR dry desquamation . 
x Subjects will permanently discontinue the inta ke of study drugs and be withdrawn from 
the study. No rechallenge is allowed. 
Note:  Subjects experiencing Grade 2 rash follo wing the last intake of study drug may 
continue in the study as long as they are not re-exposed to suspect study drug. 
x An unscheduled visit for initial rash evaluation (day 1 of the rash) is required. 
x Assessment of safety blood samples by the lo cal laboratory is required. A copy of the 
local laboratory report should be anonymized  and will be retrieved by the monitor. 
x Digital pictures should be  taken within 24 hours after the onset of the rash. 
x Referral to a dermatologist is  required, preferably within 24 hours after the onset of the 
rash. A copy of the dermatologistâ€™s report s hould be anonymized and will be retrieved by 
the monitor. 
x A biopsy is performed (preferably within 24 hour s after the onset of the rash) if advised 
by the dermatologist. A copy of the biopsy report should be anonymized and will be 
retrieved by the monitor. 
x Cetirizine, levocetirizine, topical corticosteroids, or antipruritic agents may be prescribed. 
Cidara Therapeutics, Inc.  Protocol CD388.SQ.1.03 
CD388 Injection 
Amendment 1 Confidential  Page 69 of 74 x The description of the rash should be reported per â€˜Unscheduled  Visit in Case of Rashâ€™ in 
the eCRF (i.e., the initial rash assessment pages). 
For close follow-up of the rash, unscheduled visits will also be performed 1 and 7 days after the 
initial assessment of the rash. At these visits, sa fety blood samples and dig ital pictures should be 
taken. The follow-up rash assessment pages of the eCRF should be completed for all follow-up 
visits. For these and all subsequent local laboratory blood sample assessments: a copy of the 
local laboratory reports should be anonymized  and will be retrie ved by the monitor. 
If the rash is unresolved after 7 days: 
x And there is an increase in AST/ALT of 1 or 2 times the baseline value OR an increase in 
AST/ALT of less than 5 times the upper limit of normal (ULN), subjects should be 
followed weekly with repeated local lab assessments and digital pictures until resolution of the AST/ALT abnormalities. 
x And there is no increase in AST/ALT, additi onal unscheduled visits (including local lab 
assessments and digital pictur es) may be performed at the Investigatorâ€™s discretion. 
Upon resolution/stabilization of the rash, digital pictures should be taken and the final rash 
assessment pages of the e CRF should be completed. 
The subject should be advised to  contact the Investigator imme diately if the rash fails to 
resolve (after more than 2 weeks), if there is  any worsening of the rash, if any systemic 
signs or allergic symptoms develop, or if mucosal involvement develops. 
In case the rash evolves from a Grade 2 to a Gr ade 3â€“4 rash, additional unscheduled visits must 
be conducted according to the guidelines for Grade 3â€“4 rash. 
Grade 3 or Grade 4 Rash 
A Grade 3 rash is defined as: 
x vesiculation, moist desquamation, or ulceration  OR 
x cutaneous event with one of the following  (revised by the Sponsor): 
 elevations in AST/ALT more than 2 u baseline value and Â• uULN 
 fever >38Â°C or 100Â°F 
 eosinophils >1000/mm
3 
 serum sickness-like reaction 
A Grade 4 rash is defined as: 
x exfoliative dermatitis OR 
x a generalized rash with mucous membrane involvement OR 
x erythema multiforme OR 
x Stevens-Johnson Syndrome OR 
x rash associated with necrosis requiring surgery 
Cidara Therapeutics, Inc.  Protocol CD388.SQ.1.03 
CD388 Injection 
Amendment 1 Confidential  Page 70 of 74 x Subjects will permanently discontinue the intake of all study drug(s) and be withdrawn 
from the study with Grade 3 or 4 rash identified. No recha llenge is allowed. 
x An unscheduled visit for initial rash evaluation (day 1 of the rash) is required. 
x Assessment of safety blood samples by the local laboratory is required on the day of initial 
rash evaluation and the day thereafter (days 1 and 2 of the rash), and as indicated below. 
A copy of the local laboratory report should be anonymized and will be retrieved by the 
monitor. 
x Digital pictures should be take n within 24 hours after the onset of the rash and on day 1 of 
the rash, and as indicated below. 
x Referral to a dermatologist is required, preferably within 24 hours after the onset of the rash. A copy of the dermatologistâ€™s report should be anonymized and will be retrieved by the 
monitor. 
x A biopsy should be performed within 24 hours af ter the onset of the rash. A copy of the 
biopsy report should be anonymized and will be retrieved by the monitor. 
x Appropriate manageme nt should be undertaken and subjects should be followed until 
resolution of the rash. 
x The description of the rash shoul d be reported per â€˜Unscheduled Vi sit in Case of Rashâ€™ in the 
eCRF (i.e., the initial rash assessment pages). The follow-up rash assessment pages of the eCRF should be completed for all follow-up visits. 
For close follow-up of the rash, unscheduled visits will be performed as follows: 
x Follow-up visits on days 2, 3, and 4 of the rash are required. Additional safety blood samples and digital pictures are to be taken on these days only if the subjectâ€™s AST/ALT on day 1 
and/or day 2 of rash >2u  EDVHOLQHYDOXHDQGRUÂ•  uULN and/or in case of rash progression. 
For these and all subsequent local laboratory blood sample assessments : a copy of the local 
laboratory report should be anonymized a nd will be retrieved by the monitor. 
x A follow-up visit on day 6 of the rash is re quired and additional sa fety blood samples 
and digital pictures are to be  taken regardless of the day 1/2 AST/ALT levels or rash 
progression. 
x Thereafter, weekly follow-up visits are required (or more frequently at the Investigatorâ€™s 
discretion) as long as Grade 3â€“4 rash is pr esent. Once Grade 3â€“4 rash has resolved to 
Grade Â”2, follow-up should be performed according to the instructions for follow-up visits 
for Grade 1 or Grade 2 rash, respectively. 
x As long as the rash remains Grade 3 or 4, add itional safety blood sample s and digital pictures 
are required at these weekly follow-up visits only if the subjectâ€™s AST/ALT on day 6 of rash 
is still >2u EDVHOLQHYDOXHDQGRUÂ•  uULN and/or in case of rash progression, until 
resolution or stabilization of  the AST/ALT elevations. 
Upon resolution/stabilization of the rash, digital pictures should be taken and the final rash 
assessment pages of the e CRF should be completed. 
Cidara Therapeutics, Inc.  Protocol CD388.SQ.1.03 
CD388 Injection 
Amendment 1 Confidential  Page 71 of 74 Subjects should be advised to contact the Investigator immediately if they notice any 
worsening of the rash. 
A complete summary of the guidelines for rash management is given in Appendix 5 . 
Cidara Therapeutics, Inc.  Protocol CD388.SQ.1.03 
CD388 Injection 
Amendment 1 Confidential  Page 72 of 74 APPENDIX 5.  VISIT SCHEDULE FOR RASH MANAGEMENT FOR 
ADULT SUBJECTS 
This visit schedule summarizes the visits and assessm ents to be performed in case of rash. At the 
Investigatorâ€™s discretion, additional visits and assessments may be perfo rmed. For all rashes, 
please also complete the specific rash assessment pages of the eCRF for all visits. Local 
laboratory blood sample assessments will be documented/collected  as described in the text 
above. 
 Grade 1 Rash Grade 2 Rash Grade 3 or 4 Rash 
Rash day 1 a x Study drug(s) MAY  
be CONTINUED . 
x Unscheduled visit 
for initial rash 
evaluation 
REQUIRED . 
x Assessment of safety blood sample 
by local laboratory 
REQUIRED . 
x Digital pictures REQUIRED  
(within 24 h). 
x Referral to dermatologist ONLY IF rash 
diagnosis uncertain 
(within 24 h). x Study drug(s) MUST  be permanently 
DISCONTINUED  if the subject has 
a persistent (i.e., >5 days with no 
response to treatment) Grade Â•2 
b 
rash considered related to CD388 by the Investigator. Rechallenge is NOT 
ALLOWED.  
x Unscheduled visit for initial rash evaluation REQUIRED . 
x Assessment of safety blood sample by local laboratory REQUIRED . 
x Digital pictures REQUIRED  
(within 24 h). 
x Referral to dermatologist REQUIRED  (within 24 h). 
x Biopsy IF ADVISED  by 
dermatologist (within 24 h). x Study drug(s) MUST  be 
permanently DISCONTINUED . 
Rechallenge is NOT ALLOWED . 
x Unscheduled visit for initial rash evaluation REQUIRED . 
x Assessment of safety blood sample by local laboratory REQUIRED . 
x Digital pictures REQUIRED  
(within 24 h). 
x Referral to dermatologist REQUIRED  (within 24 h). 
x Biopsy REQUIRED (within 24 h). 
Rash day 2 x Follow-up visit REQUIRED . 
x Assessment of safety blood sample by local laboratory REQUIRED . 
x Digital pictures REQUIRED.  x Follow-up visit REQUIRED . 
x Assessment of safety blood sample by local laboratory REQUIRED . 
x Digital pictures REQUIRED.  x Follow-up visit REQUIRED . 
x Assessment of safety blood sample by local laboratory REQUIRED . 
x Digital pictures REQUIRED.  
Rash day 3 No Rash follow-up visit required 
c No Rash follow-up visit required c x Follow-up visit REQUIRED . 
x Assessment of safety blood sample by local laboratory and digital pictures REQUIRED  only if on 
days 1 and/or 2 of rash AST/ALT 
>2Ã® baseline value, AND/OR 
5 Ã® ULN, AND/OR in case of rash 
progression. 
Rash day 4 No Rash follow-up visit required 
c No Rash follow-up visit required c x Follow-up visit REQUIRED . 
x Assessment of safety blood sample by local laboratory and digital 
pictures REQUIRED  only if on 
days 1 and/or 2 of rash AST/ALT 
>2Ã® baseline value, AND/OR 
5 Ã® ULN, AND/OR in case of rash 
progression. 
Cidara Therapeutics, Inc.  Protocol CD388.SQ.1.03 
CD388 Injection 
Amendment 1 Confidential  Page 73 of 74  Grade 1 Rash Grade 2 Rash Grade 3 or 4 Rash 
Rash day 5 No Rash follow-up visit 
required c No Rash follow-up visit required c x Follow-up visit REQUIRED .  
x Assessment of safety blood sample by local laboratory and digital 
pictures REQUIRED  only if on 
days 1 and/or 2 of rash AST/ALT 
>2Ã® baseline value, AND/OR 
5 Ã® ULN, AND/OR in case of rash 
progression.  
Rash day 6 No Rash follow-up visit required 
c No Rash follow-up visit required c x Follow-up visit REQUIRED . 
x Assessment of safety blood sample by local laboratory REQUIRED . 
x Digital pictures REQUIRED.  
Rash day 7 No Rash follow-up visit required 
c No Rash follow-up visit required c No Rash follow-up visit required 
Rash day 8 x Follow-up visit REQUIRED  
c 
x Assessment of safety blood sample by local laboratory REQUIRED . 
x Digital pictures REQUIRED.  x Follow-up visit REQUIRED  
c 
x Assessment of safety blood sample by local laboratory REQUIRED . 
x Digital pictures REQUIRED.  No Rash follow-up visit required 
Further 
Visits If rash is unresolved after second follow-up visit, further visits (with local lab assessments and digital 
pictures) at the 
Investigatorâ€™s discretion. 
c If rash is unresolved after second follow-up visit: 
:LWK$67$/7LQFUHDVHÂ”Ã®  baseline 
value OR AST/ALT increase 
<5 Ã® ULN: c 
x Weekly assessment of safety blood 
sample by local laboratory 
REQUIRED  until resolution of 
AST/ALT abnormalities. 
x Weekly digital pictures REQUIRED  
until resolution of AST/ALT 
abnormalities. 
Without AST/ALT increase: further 
visits at the Investigatorâ€™s discretion. c x Weekly follow-up visits REQUIRED  until resolution of 
Grade 3â€“4 rash to Grade Â”
(further follow-up visits according 
to Grade 1 or Grade 2 rash 
instructions) 
x Weekly assessment of safety blood sample by local laboratory and 
digital pictures REQUIRED  as 
long as Grade 3 or 4 rash is present but only if on day 6 of rash 
AST/ALT >2 Ã® baseline value, 
AND/OR 5 Ã® ULN, AND/OR in 
case of rash progression, until resolution of AST/ALT abnormalities. 
Upon Rash 
Resolution/
Stabilization d Complete final rash assessment pages of the 
eCRF/eSource and take 
digital pictures. Complete final rash assessment pages of the eCRF/eSource and take digital 
pictures. Complete final rash assessment pages 
of the eCRF/eSource and take digital 
pictures. 
a. Note that Day 0 of the rash is the first day of Investigator assessment and not the first day of rash as reported by the subject. 
b. All grades in this list are per the DAIDS Toxicity Grading Scale ( DAIDS 2017 ). 
c. In case rash progresses from a Grade 1 or a Grade 2 to a higher grade, start follow-up schedule for Grade 2, 3, or 4 rash as appropriate. 
d. Stabilization: to be agreed upon in collaboration with the Sponsor 
Cidara Therapeutics, Inc. Protocol CD388.SQ.1.03
CD388 Injection
Amendment 1 Confidential Page 74 of 74APPENDIX 6. INVESTIGATOR SIGNATURE
I have read and understand Protocol CD 388.SQ.1.03 and I agree to the following:
xTo conduct the trial in compliance with GCP, with applicable regulatory requirement(s), 
with the protocol agreed to by the Sponsor  and given approval/fa vorable opinion by the 
IRB/IEC
xTo comply with procedures fo r data recording and reporting
xTo permit monitoring, auditing, and insp ection by the Sponsor, its designated 
representatives, and regulatory authorities 
xTo retain the essential documents in the I nvestigator/institution files until the Sponsor 
informs the Investigator or institution that these documents are no longer needed
INVESTIGATOR SIGNATURE
Investigator Signature Date
Investigator Printed Name
Site Information
Site Number:
Site Name:
Site Address:Altasciences Clinical Los Angeles, Inc.14-Dec-2022
5630 Cerritos Avenue
Cypress, CA 90630
David Kim, MD
01229
Certificate Of Completion
Envelope Id: E29F400E70104117B194ECAEEEF2213B Status: Completed
Subject: CD388.SQ.1.03_Final Protocol_AM1_12-Dec-2022
Source Envelope: Document Pages: 74 Signatures: 2 Envelope Originator: 
Certificate Pages: 3 Initials: 0 Joaquin Sosa
AutoNav: EnabledEnvelopeId Stamping: DisabledTime Zone: (UTC-08:00) Pacific Time (US & Canada)6310 Nancy Ridge DrSTE 101San Diego, CA  92121jsosa@cidara.com
IP Address: 136.49.136.134 
Record Tracking
Status: Original
             12/13/2022 4:06:35 PMHolder: Joaquin Sosa             jsosa@cidara.comLocation: DocuSign
Signer Events Signature Timestamp
Taylor Sandison, MD. MPHtsandison@cidara.comChief Medical OfficerCidara Therapeutics Part 11Security Level: Email, Account Authentication 
(Required)
Signature Adoption: Pre-selected Style
Signature ID: 032CF6C2-F867-4C8B-8C6E-30671D5BC544Using IP Address: 192.124.167.250
With Signing Authentication via DocuSign password
With Signing Reasons (on each tab):    I approve this documentSent: 12/13/2022 4:23:12 PMViewed: 12/14/2022 7:56:14 AM Signed: 12/14/2022 7:56:55 AM
Electronic Record and Signature Disclosure: 
      Not Offered via DocuSign
David Kim, MD
YKim@altasciences.com
Principal Investigator
Security Level: Email, Account Authentication 
(Required)
Signature Adoption: Pre-selected Style
Signature ID: FB75287A-18B4-4714-9906-13666AE1A8AEUsing IP Address: 208.127.236.214Signed using mobileWith Signing Authentication via DocuSign passwordWith Signing Reasons (on each tab):    I approve this documentSent: 12/14/2022 7:56:58 AM
Viewed: 12/14/2022 8:42:43 AM 
Signed: 12/14/2022 8:44:36 AM
Electronic Record and Signature Disclosure: 
      Accepted: 12/14/2022 8:42:43 AM
      ID: df255c43-8d38-4720-af2f-a92d6cdcaf56
In Person Signer Events Signature Timestamp
Editor Delivery Events Status Timestamp
Agent Delivery Events Status Timestamp
Intermediary Delivery Events Status Timestamp
Certified Delivery Events Status Timestamp
Carbon Copy Events Status Timestamp
Margarita Ramos
MRamos@altasciences.comScientific Project ManagerSecurity Level: Email, Account Authentication 
(Required)
Sent: 12/14/2022 8:44:39 AM
Electronic Record and Signature Disclosure: 
      Accepted: 10/7/2022 8:31:31 AM
      ID: b9f1fd8d-dfe9-4114-bdf3-d08999ca89ee
Roni Martinez
rmartinez@cidara.comManager, Document ControlCidaraSecurity Level: Email, Account Authentication 
(Required)
Sent: 12/14/2022 8:44:40 AM
Viewed: 12/14/2022 8:53:26 AM 
Electronic Record and Signature Disclosure: 
      Not Offered via DocuSign
Witness Events Signature Timestamp
Notary Events Signature Timestamp
Envelope Summary Events Status Timestamps
Envelope Sent Hashed/Encrypted 12/13/2022 4:23:12 PM
Certified Delivered Security Checked 12/14/2022 8:42:43 AM
Signing Complete Security Checked 12/14/2022 8:44:36 AM
Completed Security Checked 12/14/2022 8:44:40 AM
Payment Events Status Timestamps
Electronic Record and Signature Disclosure
ELECTRONIC RECORD AND SIGNATURE DISCLOSURE   
By accepting this notice, I am documenting that I understand and approve the following:  
1. When I sign documents or data electronically, I am accountable and responsible for all 
items thus signed. 
2. I am to be held responsible for all actions initiated under my electronic signature. 
3. I will use my electronic signature only for thos e assigned tasks that I have the education, 
training, and experience to perform. 
I will comply with the US FDA 21 CFR Part 11 and EU Annex 11 security rules for Cidara 
Therapeutics use of electronic signatures as follows:  
1. I will not share passwords and/or identification codes used to log into a system or to manifest an electronic signature for Cidara Therapeutics documents. 
2. I will immediately notify Cidara Therapeutics of any loss of misuse of passwords and/or identification codes which may have been used to log into a system or to manifest an electronic signature for Cidara Therapeutics documents. 
 	



